{"docstore/data": {"1df29f49-542f-4632-9766-56b644975a8e": {"__data__": {"id_": "1df29f49-542f-4632-9766-56b644975a8e", "embedding": null, "metadata": {"page_label": "1", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "Exhibit 10.3\n[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nManufacturing Agreement\nBetween\nAntares Pharma, Inc.\nand\nAMAG Pharmaceuticals, Inc.\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "Exhibit 10.3\n[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nManufacturing Agreement\nBetween\nAntares Pharma, Inc.\nand\nAMAG Pharmaceuticals, Inc.\n"}, "__type__": "4"}, "c982e2fa-d5ea-4eeb-bc3f-abe002c61bd5": {"__data__": {"id_": "c982e2fa-d5ea-4eeb-bc3f-abe002c61bd5", "embedding": null, "metadata": {"page_label": "2", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nMANUFACTURING AGREEMENT\nThis Manufacturing Agreement (\u201cAgreement\u201d) is made and entered into as of the 20th day of March, 2018 (the \u201cEffective\nDate\u201d) by and between Antares Pharma, Inc., a Delaware corporation, with offices located at 100 Princeton South, Suite 300,\nEwing, NJ 08628 (\u201cAntares\u201d), and AMAG Pharmaceuticals, Inc., a Delaware corporation, with a corporate address at 1100\nWinter Street, Waltham, MA 02451 (\u201cAMAG\u201d). Antares and AMAG are sometimes referred to herein individually as a \u201cParty\u201d\nand collectively as the \u201cParties\u201d.\nRecitals\nWHEREAS, AMAG is engaged in discovering, developing and marketing pharmaceutical products, including the Drug (as\ndefined below)\u037e\nWHEREAS, Antares is engaged in the research and development of certain drug delivery devices, including auto-injection\nsystems and the development and marketing of pharmaceutical products\u037e\nWHEREAS, AMAG Pharma USA, Inc. (f/k/a Lumara Health, Inc., (\u201cAMAG USA\u201d)), which was acquired by AMAG on\nNovember 12, 2014 and is a wholly-owned subsidiary of AMAG, and Antares entered into a certain Development and License\nAgreement (defined below) under which Antares granted AMAG USA an exclusive, worldwide license to Antares\u2019 VIBEX\u00ae\nQuickShot\u00ae (QS) auto-injection system or similar Device (defined below) for use with the Drug, and further under which Antares\nand AMAG USA agreed to collaborate to develop such a product\u037e\nWHEREAS, contemporaneously with the execution of this Agreement, Antares, AMAG and AMAG USA are entering into\na First Amendment to Development and License Agreement, pursuant to which, among other amendments set forth therein,\nAMAG USA assigned, and AMAG assumed, the rights and responsibilities under the Development and License Agreement (the\n\u201cFirst Amendment to Development and License Agreement\u201d)\u037e\nWHEREAS, AMAG (as the permitted assignee of the Development and License Agreement) and Antares agreed under the\nDevelopment and License Agreement to enter into this Agreement and, whereby it will provide Antares or its Subcontractor\n(defined below) with Prefilled Syringes (defined below) containing the Drug and Antares or it Subcontractor will incorporate the\nPrefilled Syringes into Devices to produce finished Products (defined below) and sample Products to supply AMAG\u2019s\nrequirements for such Products and sample Products\u037e and\nWHEREAS, AMAG wishes to purchase, and Antares wishes to supply, AMAG\u2019s requirements of the Trainers (defined\nbelow) on the terms set forth in this Agreement.\nNOW, THEREFORE, in consideration of the foregoing and the mutual covenants and promises contained in this\nAgreement, the Parties hereto agree as follows:\n- 1 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nMANUFACTURING AGREEMENT\nThis Manufacturing Agreement (\u201cAgreement\u201d) is made and entered into as of the 20th day of March, 2018 (the \u201cEffective\nDate\u201d) by and between Antares Pharma, Inc., a Delaware corporation, with offices located at 100 Princeton South, Suite 300,\nEwing, NJ 08628 (\u201cAntares\u201d), and AMAG Pharmaceuticals, Inc., a Delaware corporation, with a corporate address at 1100\nWinter Street, Waltham, MA 02451 (\u201cAMAG\u201d). Antares and AMAG are sometimes referred to herein individually as a \u201cParty\u201d\nand collectively as the \u201cParties\u201d.\nRecitals\nWHEREAS, AMAG is engaged in discovering, developing and marketing pharmaceutical products, including the Drug (as\ndefined below)\u037e\nWHEREAS, Antares is engaged in the research and development of certain drug delivery devices, including auto-injection\nsystems and the development and marketing of pharmaceutical products\u037e\nWHEREAS, AMAG Pharma USA, Inc. (f/k/a Lumara Health, Inc., (\u201cAMAG USA\u201d)), which was acquired by AMAG on\nNovember 12, 2014 and is a wholly-owned subsidiary of AMAG, and Antares entered into a certain Development and License\nAgreement (defined below) under which Antares granted AMAG USA an exclusive, worldwide license to Antares\u2019 VIBEX\u00ae\nQuickShot\u00ae (QS) auto-injection system or similar Device (defined below) for use with the Drug, and further under which Antares\nand AMAG USA agreed to collaborate to develop such a product\u037e\nWHEREAS, contemporaneously with the execution of this Agreement, Antares, AMAG and AMAG USA are entering into\na First Amendment to Development and License Agreement, pursuant to which, among other amendments set forth therein,\nAMAG USA assigned, and AMAG assumed, the rights and responsibilities under the Development and License Agreement (the\n\u201cFirst Amendment to Development and License Agreement\u201d)\u037e\nWHEREAS, AMAG (as the permitted assignee of the Development and License Agreement) and Antares agreed under the\nDevelopment and License Agreement to enter into this Agreement and, whereby it will provide Antares or its Subcontractor\n(defined below) with Prefilled Syringes (defined below) containing the Drug and Antares or it Subcontractor will incorporate the\nPrefilled Syringes into Devices to produce finished Products (defined below) and sample Products to supply AMAG\u2019s\nrequirements for such Products and sample Products\u037e and\nWHEREAS, AMAG wishes to purchase, and Antares wishes to supply, AMAG\u2019s requirements of the Trainers (defined\nbelow) on the terms set forth in this Agreement.\nNOW, THEREFORE, in consideration of the foregoing and the mutual covenants and promises contained in this\nAgreement, the Parties hereto agree as follows:\n- 1 -\n"}, "__type__": "4"}, "e376513c-5f5c-48b2-85ec-e29f792187c7": {"__data__": {"id_": "e376513c-5f5c-48b2-85ec-e29f792187c7", "embedding": null, "metadata": {"page_label": "3", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nARTICLE 1\nINTERPRETATION\n1.1 Definitions. Capitalized terms used in this Agreement and not otherwise defined in this Section 1.1 shall have the meanings\nset out in the Development and License Agreement. The following terms shall, unless the context otherwise requires, have\nthe respective meanings set out below and grammatical variations of such terms shall have corresponding meanings:\n\u201c[***]\u201d has the meaning specified in Section 3.2(c)\u037e\n\u201c[***]\u201d has the meaning specified in Section 3.2(c)\u037e\n[***]\n\u201cAgreement\u201d has the meaning specified in the Preamble\u037e\n\u201cAMAG\u201d has the meaning specified in the Preamble\u037e\n\u201cAMAG Indemnitees\u201d has the meaning specified in Section 9.2\u037e\n\u201cAMAG USA\u201d has the meaning specified in the Recitals\u037e\n\u201cAMAG Quality Tasks\u201d means AMAG\u2019s quality, testing and release obligations set forth in Section 2.6(b) and in the Quality\nAgreement\u037e\n\u201cAnnual Product Review Report\u201d means the annual product review report as described in Title 21 of the United States Code of\nFederal Regulations, Section 211.180(e)\u037e\n\u201cAnnual Report\u201d means the annual report as described in Title 21 of the United States Code of Federal Regulations, Section\n314.81(b)(2)\u037e\n\u201cAntares\u201d has the meaning specified in the Preamble\u037e\n\u201cAntares\u2019 Fully Burdened Manufacturing Costs\u201d means those costs actually incurred by Antares related directly to the\nacquisition of materials and their conversion into Products, sample Products or Trainers, as the case may be. [***]\u037e\n\u201cAntares Indemnitees\u201d has the meaning specified in Section 9.1\u037e\n\u201cBatch Record\u201d means a detailed, step-by-step description of the entire assembly, packaging and labelling process for the\nProducts and sample Products which explains how such Products or sample Products (as the case may be) were assembled,\npackaged and labelled, indicating specific types and quantities of Components, additional materials, processing parameters, in-\nprocess quality controls, and other relevant controls\u037e\n- 2 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nARTICLE 1\nINTERPRETATION\n1.1 Definitions. Capitalized terms used in this Agreement and not otherwise defined in this Section 1.1 shall have the meanings\nset out in the Development and License Agreement. The following terms shall, unless the context otherwise requires, have\nthe respective meanings set out below and grammatical variations of such terms shall have corresponding meanings:\n\u201c[***]\u201d has the meaning specified in Section 3.2(c)\u037e\n\u201c[***]\u201d has the meaning specified in Section 3.2(c)\u037e\n[***]\n\u201cAgreement\u201d has the meaning specified in the Preamble\u037e\n\u201cAMAG\u201d has the meaning specified in the Preamble\u037e\n\u201cAMAG Indemnitees\u201d has the meaning specified in Section 9.2\u037e\n\u201cAMAG USA\u201d has the meaning specified in the Recitals\u037e\n\u201cAMAG Quality Tasks\u201d means AMAG\u2019s quality, testing and release obligations set forth in Section 2.6(b) and in the Quality\nAgreement\u037e\n\u201cAnnual Product Review Report\u201d means the annual product review report as described in Title 21 of the United States Code of\nFederal Regulations, Section 211.180(e)\u037e\n\u201cAnnual Report\u201d means the annual report as described in Title 21 of the United States Code of Federal Regulations, Section\n314.81(b)(2)\u037e\n\u201cAntares\u201d has the meaning specified in the Preamble\u037e\n\u201cAntares\u2019 Fully Burdened Manufacturing Costs\u201d means those costs actually incurred by Antares related directly to the\nacquisition of materials and their conversion into Products, sample Products or Trainers, as the case may be. [***]\u037e\n\u201cAntares Indemnitees\u201d has the meaning specified in Section 9.1\u037e\n\u201cBatch Record\u201d means a detailed, step-by-step description of the entire assembly, packaging and labelling process for the\nProducts and sample Products which explains how such Products or sample Products (as the case may be) were assembled,\npackaged and labelled, indicating specific types and quantities of Components, additional materials, processing parameters, in-\nprocess quality controls, and other relevant controls\u037e\n- 2 -\n"}, "__type__": "4"}, "65e9c1b8-a1c9-4d1b-9dad-0c204a02ea11": {"__data__": {"id_": "65e9c1b8-a1c9-4d1b-9dad-0c204a02ea11", "embedding": null, "metadata": {"page_label": "4", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n\u201cBinding Forecast\u201d has the meaning specified in Section 3.2(a)\u037e\n\u201c[***]\u201d has the meaning specified in Section 3.2(c)\u037e\n\u201cBusiness Day\u201d means a day other than a Saturday, Sunday or a day that is a federal holiday in the United States\u037e\n\u201cCalendar Quarter\u201d means a three-month period ending on March 31, June 30, September 30 or December 31\u037e\n\u201cCalendar Year\u201d means a calendar year occurring after the Effective Date\u037e provided, however, the first Calendar Year means the\nperiod from the Effective Date up to and including December 31 of the same calendar year in which the Effective Date occurs\u037e\n\u201c[***]\u201d has the meaning specified in Section 3.2(c)\u037e\n\u201cCertificate of Analysis (Device)\u201d means a document signed by an authorized representative of Antares or the Subcontractor\nthat conducted the applicable analysis, in reasonable and customary form, that: (i) describes the specifications for, and testing\nmethods applied to, the quantity of each of the Major Device Components manufactured by or on behalf of Antares pursuant to\nthis Agreement, and the results of such testing, and (ii) certifies that such quantity of each of the Major Device Components was\nmanufactured in accordance with cGMP, all other Applicable Laws, and the Product Specifications\u037e\n\u201cCertificate of Analysis (PFS Manufacture)\u201d means a document signed by an authorized representative of AMAG, its agent\nor its permitted subcontractor that conducted the applicable analysis, in reasonable and customary form, that: (i) describes the\nspecifications for, and testing methods applied to the Drug manufactured by or on behalf of AMAG pursuant to this Agreement,\nand the results of such testing, and (ii) certifies that such quantity of Drug was manufactured in accordance with cGMP, all other\nApplicable Laws, and the Product Specifications\u037e\n\u201cCertificate of Analysis (PFS ID Testing)\u201d means a document signed by an authorized representative of AMAG, its agent or\nits permitted subcontractor that conducted the applicable analysis, in reasonable and customary form, that describes the\nspecifications for, and testing methods applied to, the Drug manufactured by or on behalf of AMAG pursuant to this Agreement\nfor identification of the Drug, and the results of such testing\u037e\n\u201cCertificate of Analysis (Product)\u201d means a document signed by an authorized representative of AMAG, its agent or its\npermitted subcontractor that conducted the applicable analysis, in reasonable and customary form, that: (i) describes the\nspecifications for, and testing methods applied to, the quantity of Product and/or sample Product manufactured by or on behalf of\nAntares pursuant to this Agreement, and the results of such testing, and (ii) certifies that such quantity of Product and/or sample\nProduct was\n- 3 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n\u201cBinding Forecast\u201d has the meaning specified in Section 3.2(a)\u037e\n\u201c[***]\u201d has the meaning specified in Section 3.2(c)\u037e\n\u201cBusiness Day\u201d means a day other than a Saturday, Sunday or a day that is a federal holiday in the United States\u037e\n\u201cCalendar Quarter\u201d means a three-month period ending on March 31, June 30, September 30 or December 31\u037e\n\u201cCalendar Year\u201d means a calendar year occurring after the Effective Date\u037e provided, however, the first Calendar Year means the\nperiod from the Effective Date up to and including December 31 of the same calendar year in which the Effective Date occurs\u037e\n\u201c[***]\u201d has the meaning specified in Section 3.2(c)\u037e\n\u201cCertificate of Analysis (Device)\u201d means a document signed by an authorized representative of Antares or the Subcontractor\nthat conducted the applicable analysis, in reasonable and customary form, that: (i) describes the specifications for, and testing\nmethods applied to, the quantity of each of the Major Device Components manufactured by or on behalf of Antares pursuant to\nthis Agreement, and the results of such testing, and (ii) certifies that such quantity of each of the Major Device Components was\nmanufactured in accordance with cGMP, all other Applicable Laws, and the Product Specifications\u037e\n\u201cCertificate of Analysis (PFS Manufacture)\u201d means a document signed by an authorized representative of AMAG, its agent\nor its permitted subcontractor that conducted the applicable analysis, in reasonable and customary form, that: (i) describes the\nspecifications for, and testing methods applied to the Drug manufactured by or on behalf of AMAG pursuant to this Agreement,\nand the results of such testing, and (ii) certifies that such quantity of Drug was manufactured in accordance with cGMP, all other\nApplicable Laws, and the Product Specifications\u037e\n\u201cCertificate of Analysis (PFS ID Testing)\u201d means a document signed by an authorized representative of AMAG, its agent or\nits permitted subcontractor that conducted the applicable analysis, in reasonable and customary form, that describes the\nspecifications for, and testing methods applied to, the Drug manufactured by or on behalf of AMAG pursuant to this Agreement\nfor identification of the Drug, and the results of such testing\u037e\n\u201cCertificate of Analysis (Product)\u201d means a document signed by an authorized representative of AMAG, its agent or its\npermitted subcontractor that conducted the applicable analysis, in reasonable and customary form, that: (i) describes the\nspecifications for, and testing methods applied to, the quantity of Product and/or sample Product manufactured by or on behalf of\nAntares pursuant to this Agreement, and the results of such testing, and (ii) certifies that such quantity of Product and/or sample\nProduct was\n- 3 -\n"}, "__type__": "4"}, "84df9f27-aff5-4154-b7d6-cd797ebd3d52": {"__data__": {"id_": "84df9f27-aff5-4154-b7d6-cd797ebd3d52", "embedding": null, "metadata": {"page_label": "5", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nmanufactured in accordance with cGMP, all other Applicable Laws, and the Product Specifications\u037e\n\u201cCertificate of Conformance (Device) \u201d means the document provided to AMAG by Antares or the Subcontractor that\nconducted the applicable review, as the case may be, that certifies each batch of each of the Major Device Components was\nmanufactured in compliance with the cGMP, all other Applicable Laws, and the Product Specifications\u037e\n\u201cCertificate of Conformance (Product)\u201d means the document provided to AMAG by Antares or the Subcontractor that\nconducted the applicable review, as the case may be, that certifies each batch of Product and/or sample Product was assembled,\npackaged and labelled in compliance with the cGMP, all other Applicable Laws, and the Product Specifications\u037e\n\u201ccGMP\u201d means current good manufacturing practice and standards as provided for (and as amended from time to time) in the\n\u201cCurrent Good Manufacturing Practice Regulations\u201d of the U.S. Code of Federal Regulations Title 21 (21CFR\u00a74\u037e\n21CFR\u00a7210/211 and 21CFR\u00a7820) and in European Community Council Directive 93/42/EEC concerning medical devices, any\nU.S., European, or other applicable laws, regulations or respective guidance documents now or subsequently established by a\ngovernmental or regulatory authority, and any arrangements, additions, or clarifications\u037e\n\u201cChange Order\u201d has the meaning specified in Section 4.2(b)\u037e\n\u201cCommercially Reasonable Efforts \u201d means, with respect to each Party, such efforts and commitment of resources in\naccordance with [***] that such Party [***]. As used in this definition of \u201cCommercially Reasonable Efforts\u201d, \u201creasonable\u201d\nshall be measured by [***]. References in this Agreement to \u201ccommercially reasonable\u201d and similar formulations shall be\ndeemed to incorporate the standard set forth in this definition of \u201cCommercially Reasonable Efforts\u201d\u037e\n\u201cComponents\u201d means, collectively, [***]\u037e\n\u201cDamages\u201d has the meaning specified in Section 9.1\u037e\n\u201cDeficiency Notice\u201d has the meaning specified in Section 5.1(a)\u037e\n\u201cDelivery Date\u201d means the delivery date of a Purchase Order of Products, sample Products or Trainers as agreed upon by the\nParties pursuant to Section 3.2(b)(i) or Antares\u2019 proposed date if AMAG does not respond within the [***] set forth in Section\n3.2(b)(i)\u037e\n\u201cDevelopment and License Agreement\u201d means that certain Development and License Agreement entered into by and\nbetween the Parties dated as of September 30, 2014, as amended by the First Amendment to the Development and License\nAgreement, and as further amended by the Parties from time to time\u037e\n- 4 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nmanufactured in accordance with cGMP, all other Applicable Laws, and the Product Specifications\u037e\n\u201cCertificate of Conformance (Device) \u201d means the document provided to AMAG by Antares or the Subcontractor that\nconducted the applicable review, as the case may be, that certifies each batch of each of the Major Device Components was\nmanufactured in compliance with the cGMP, all other Applicable Laws, and the Product Specifications\u037e\n\u201cCertificate of Conformance (Product)\u201d means the document provided to AMAG by Antares or the Subcontractor that\nconducted the applicable review, as the case may be, that certifies each batch of Product and/or sample Product was assembled,\npackaged and labelled in compliance with the cGMP, all other Applicable Laws, and the Product Specifications\u037e\n\u201ccGMP\u201d means current good manufacturing practice and standards as provided for (and as amended from time to time) in the\n\u201cCurrent Good Manufacturing Practice Regulations\u201d of the U.S. Code of Federal Regulations Title 21 (21CFR\u00a74\u037e\n21CFR\u00a7210/211 and 21CFR\u00a7820) and in European Community Council Directive 93/42/EEC concerning medical devices, any\nU.S., European, or other applicable laws, regulations or respective guidance documents now or subsequently established by a\ngovernmental or regulatory authority, and any arrangements, additions, or clarifications\u037e\n\u201cChange Order\u201d has the meaning specified in Section 4.2(b)\u037e\n\u201cCommercially Reasonable Efforts \u201d means, with respect to each Party, such efforts and commitment of resources in\naccordance with [***] that such Party [***]. As used in this definition of \u201cCommercially Reasonable Efforts\u201d, \u201creasonable\u201d\nshall be measured by [***]. References in this Agreement to \u201ccommercially reasonable\u201d and similar formulations shall be\ndeemed to incorporate the standard set forth in this definition of \u201cCommercially Reasonable Efforts\u201d\u037e\n\u201cComponents\u201d means, collectively, [***]\u037e\n\u201cDamages\u201d has the meaning specified in Section 9.1\u037e\n\u201cDeficiency Notice\u201d has the meaning specified in Section 5.1(a)\u037e\n\u201cDelivery Date\u201d means the delivery date of a Purchase Order of Products, sample Products or Trainers as agreed upon by the\nParties pursuant to Section 3.2(b)(i) or Antares\u2019 proposed date if AMAG does not respond within the [***] set forth in Section\n3.2(b)(i)\u037e\n\u201cDevelopment and License Agreement\u201d means that certain Development and License Agreement entered into by and\nbetween the Parties dated as of September 30, 2014, as amended by the First Amendment to the Development and License\nAgreement, and as further amended by the Parties from time to time\u037e\n- 4 -\n"}, "__type__": "4"}, "833a5be3-8773-4bb2-82bf-8142494da7f1": {"__data__": {"id_": "833a5be3-8773-4bb2-82bf-8142494da7f1", "embedding": null, "metadata": {"page_label": "6", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n\u201cDevice\u201d means the VIBEX\u00ae QS auto-injection system device, consisting of the Major Device Components, designed and\ndeveloped to incorporate a Prefilled Syringe for delivery of the Drug, and any improvements or modifications thereof made\npursuant to the Development and License Agreement, or such other Antares-proprietary device as agreed to by Antares designed\nand developed to deliver the Drug pursuant to the Development and License Agreement, as further set forth on Exhibit B. For\ngreater certainty, the Major Device Components are intended to be assembled with the Prefilled Syringe to produce a finished\nProduct\u037e\n\u201cDHF\u201d has the meaning specified in the Development and License Agreement\u037e\n\u201cDMF\u201d has the meaning specified in the Development and License Agreement and is expanded to further clarify that a DMF is\nequivalent to an \u201cMAF\u201d or Master File\u037e\n\u201cDrug\u201d means 17-alpha hydroxyprogesterone caproate\u037e\n\u201cEffective Date\u201d has the meaning specified in the Preamble\u037e\n[***]\n\u201cExcess Order\u201d has the meaning specified in Section 3.2(b)(i)\u037e\n\u201cFirm Orders\u201d means any Purchase Order accepted by Antares pursuant to Section 3.2(b)(i) (as evidenced by an Order\nAcceptance), including any Excess Orders agreed to by Antares in an Order Acceptance, with the Delivery Date as set forth in\nSection 3.2(b)(i)\u037e\n\u201cFirst Amendment to the Development and License Agreement\u201d has the meaning specified in the Recitals\u037e\n\u201cForce Majeure Event\u201d has the meaning specified in Section 12.4\u037e\n\u201cForecast\u201d has the meaning specified in Section 3.2(a)\u037e\n\u201c[***]\u201d has the meaning specified in Section 4.6\u037e\n\u201c[***]\u201d has the meaning specified in Section 3.2(c)\u037e\n\u201c[***]\u201d has the meaning specified in Section 3.2(c)\u037e\n\u201cInvoice\u201d has the meaning specified in Section 4.2(a)\u037e\n\u201c[***]\u201d has the meaning specified in Section 3.2(c)\u037e\n\u201cLatent Defects\u201d has the meaning specified in Section 5.1(a)\u037e\n- 5 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n\u201cDevice\u201d means the VIBEX\u00ae QS auto-injection system device, consisting of the Major Device Components, designed and\ndeveloped to incorporate a Prefilled Syringe for delivery of the Drug, and any improvements or modifications thereof made\npursuant to the Development and License Agreement, or such other Antares-proprietary device as agreed to by Antares designed\nand developed to deliver the Drug pursuant to the Development and License Agreement, as further set forth on Exhibit B. For\ngreater certainty, the Major Device Components are intended to be assembled with the Prefilled Syringe to produce a finished\nProduct\u037e\n\u201cDHF\u201d has the meaning specified in the Development and License Agreement\u037e\n\u201cDMF\u201d has the meaning specified in the Development and License Agreement and is expanded to further clarify that a DMF is\nequivalent to an \u201cMAF\u201d or Master File\u037e\n\u201cDrug\u201d means 17-alpha hydroxyprogesterone caproate\u037e\n\u201cEffective Date\u201d has the meaning specified in the Preamble\u037e\n[***]\n\u201cExcess Order\u201d has the meaning specified in Section 3.2(b)(i)\u037e\n\u201cFirm Orders\u201d means any Purchase Order accepted by Antares pursuant to Section 3.2(b)(i) (as evidenced by an Order\nAcceptance), including any Excess Orders agreed to by Antares in an Order Acceptance, with the Delivery Date as set forth in\nSection 3.2(b)(i)\u037e\n\u201cFirst Amendment to the Development and License Agreement\u201d has the meaning specified in the Recitals\u037e\n\u201cForce Majeure Event\u201d has the meaning specified in Section 12.4\u037e\n\u201cForecast\u201d has the meaning specified in Section 3.2(a)\u037e\n\u201c[***]\u201d has the meaning specified in Section 4.6\u037e\n\u201c[***]\u201d has the meaning specified in Section 3.2(c)\u037e\n\u201c[***]\u201d has the meaning specified in Section 3.2(c)\u037e\n\u201cInvoice\u201d has the meaning specified in Section 4.2(a)\u037e\n\u201c[***]\u201d has the meaning specified in Section 3.2(c)\u037e\n\u201cLatent Defects\u201d has the meaning specified in Section 5.1(a)\u037e\n- 5 -\n"}, "__type__": "4"}, "905ae161-c71b-4477-8324-7086a6f969ce": {"__data__": {"id_": "905ae161-c71b-4477-8324-7086a6f969ce", "embedding": null, "metadata": {"page_label": "7", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n\u201cLong Lead Time Materials\u201d means [***], a description of which are set forth on Exhibit A (as such exhibit may be amended\nfrom time to time by the mutual written agreement of the Parties), [***]\u037e\n\u201cMajor Device Components\u201d means the following Components of the Device: [***].\n\u201cManufacture(d) at Risk\u201d has the meaning specified in Section 3.7(a)\u037e\n\u201cManufacturing Services\u201d means the manufacturing, quality control and quality assurance, storage, labelling, packaging,\nassembly and related services, to be performed by Antares or its Subcontractor as contemplated in this Agreement and described\nin the Specifications and the Quality Agreement, required to manufacture Devices and produce and supply Trainers, Products and\nsample Products from such Devices, Prefilled Syringes and Components. For the avoidance of doubt, the \u201cManufacturing\nServices\u201d specifically excludes the AMAG Quality Tasks and all other services, activities or tasks to be performed by or on behalf\nof AMAG set forth in this Agreement or as otherwise described in the Specifications or the Quality Agreement\u037e\n\u201cManufacturing Site\u201d means [***] or such other facility owned and operated by Antares or a Subcontractor on behalf of\nAntares under this Agreement [***].\n\u201cNon-Binding Forecast\u201d has the meaning specified in Section 3.2(a)\u037e\n\u201cNon-Cancellable Non-Returnable Materials\u201d or \u201cNCNR Materials\u201d means [***]\u037e\n[***]\n\u201cOrder Acceptance\u201d has the meaning specified in Section 3.2(b)(i)\u037e\n\u201cOther Approved Antares Product\u201d has the meaning specified in Section 4.6(a)\u037e\n\u201cParties\u201d and \u201cParty\u201d have the meanings specified in the Preamble\u037e\n\u201cPerson\u201d means any natural person, a corporation, a partnership, a trust, a joint venture, a limited liability company, any\nGovernmental Authority or any other entity or organization\u037e\n\u201c[***]\u201d has the meaning specified in Section 2.1(b)\u037e\n\u201cPrefilled Syringe\u201d means the prefilled syringe containing the formulated Drug for incorporation into the Device, as further set\nforth in the Product Specifications\u037e\n\u201cPrior Orders\u201d has the meaning specified in Section 3.2(c)\u037e\n\u201cProduct(s)\u201d means the fully packaged Device for auto-injection delivery of the Drug incorporating a Prefilled Syringe and other\napplicable Components listed on Exhibit B\n- 6 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n\u201cLong Lead Time Materials\u201d means [***], a description of which are set forth on Exhibit A (as such exhibit may be amended\nfrom time to time by the mutual written agreement of the Parties), [***]\u037e\n\u201cMajor Device Components\u201d means the following Components of the Device: [***].\n\u201cManufacture(d) at Risk\u201d has the meaning specified in Section 3.7(a)\u037e\n\u201cManufacturing Services\u201d means the manufacturing, quality control and quality assurance, storage, labelling, packaging,\nassembly and related services, to be performed by Antares or its Subcontractor as contemplated in this Agreement and described\nin the Specifications and the Quality Agreement, required to manufacture Devices and produce and supply Trainers, Products and\nsample Products from such Devices, Prefilled Syringes and Components. For the avoidance of doubt, the \u201cManufacturing\nServices\u201d specifically excludes the AMAG Quality Tasks and all other services, activities or tasks to be performed by or on behalf\nof AMAG set forth in this Agreement or as otherwise described in the Specifications or the Quality Agreement\u037e\n\u201cManufacturing Site\u201d means [***] or such other facility owned and operated by Antares or a Subcontractor on behalf of\nAntares under this Agreement [***].\n\u201cNon-Binding Forecast\u201d has the meaning specified in Section 3.2(a)\u037e\n\u201cNon-Cancellable Non-Returnable Materials\u201d or \u201cNCNR Materials\u201d means [***]\u037e\n[***]\n\u201cOrder Acceptance\u201d has the meaning specified in Section 3.2(b)(i)\u037e\n\u201cOther Approved Antares Product\u201d has the meaning specified in Section 4.6(a)\u037e\n\u201cParties\u201d and \u201cParty\u201d have the meanings specified in the Preamble\u037e\n\u201cPerson\u201d means any natural person, a corporation, a partnership, a trust, a joint venture, a limited liability company, any\nGovernmental Authority or any other entity or organization\u037e\n\u201c[***]\u201d has the meaning specified in Section 2.1(b)\u037e\n\u201cPrefilled Syringe\u201d means the prefilled syringe containing the formulated Drug for incorporation into the Device, as further set\nforth in the Product Specifications\u037e\n\u201cPrior Orders\u201d has the meaning specified in Section 3.2(c)\u037e\n\u201cProduct(s)\u201d means the fully packaged Device for auto-injection delivery of the Drug incorporating a Prefilled Syringe and other\napplicable Components listed on Exhibit B\n- 6 -\n"}, "__type__": "4"}, "d1fdc44d-9a11-4eb9-9f3b-6360aa8d35e3": {"__data__": {"id_": "d1fdc44d-9a11-4eb9-9f3b-6360aa8d35e3", "embedding": null, "metadata": {"page_label": "8", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nhereto, as such exhibit may be amended from time to time by the mutual written agreement of the Parties\u037e\n\u201cProduct Specifications\u201d means, as set forth on Exhibit B hereto, for each Product, with AMAG having primary responsibility\nwith respect to the Drug and Prefilled Syringe, and Antares having primary responsibility with respect to the Devices and\nComponents, the following documents relating to such Product:\n(a) specifications for Devices, Prefilled Syringes and Components\u037e\n(b) the Product Specifications\u037e and\n(c) storage, packaging, prescribing information and label specifications and requirements\u037e and\nall as updated, amended and revised from time to time by the Parties in writing in accordance with the terms of this Agreement,\nand in all cases including compliance with all Applicable Laws and the Quality Agreement\u037e\n\u201cQuality Agreement\u201d has the meaning specified in Section 2.6(a)\u037e\n\u201cRecall\u201d means any action (i) by AMAG to recover title to or possession of quantities of the Products, sample Products and/or\nTrainers sold or shipped to third parties (including, without limitation, the voluntary withdrawal of Products, sample Products\nand/or Trainers) from the market)\u037e or (ii) by any Regulatory Authorities to detain or destroy any of the Products and/or the sample\nProducts. Recall shall also include any action by either Party to refrain from selling or shipping quantities of the Products, sample\nProducts and/or Trainers to third parties which would have been subject to a Recall if sold or shipped\u037e\n\u201cSafety Stock\u201d has the meaning specified in Section 3.6(a)\u037e\n\u201cSecond Source Supplier\u201d has the meaning specified in Section 3.9\u037e\n\u201c[***]\u201d has the meaning specified in Section 2.1(b)\u037e\n\u201cSpecifications\u201d means the Product Specifications with respect to the Product and sample Product, and the Trainer\nSpecifications with respect to the Trainers, as the case may be\u037e\n\u201cSubcontractor\u201d has the meaning specified in Section 2.1(b)\u037e\n\u201cSupply Failure\u201d has the meaning specified in Section 3.5(a)\u037e\n\u201cSupply Failure Remedy Option\u201d has the meaning specified in Section 3.5(b)\u037e\n[***]\n\u201cTerm\u201d has the meaning specified in Section 7.1\u037e\n- 7 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nhereto, as such exhibit may be amended from time to time by the mutual written agreement of the Parties\u037e\n\u201cProduct Specifications\u201d means, as set forth on Exhibit B hereto, for each Product, with AMAG having primary responsibility\nwith respect to the Drug and Prefilled Syringe, and Antares having primary responsibility with respect to the Devices and\nComponents, the following documents relating to such Product:\n(a) specifications for Devices, Prefilled Syringes and Components\u037e\n(b) the Product Specifications\u037e and\n(c) storage, packaging, prescribing information and label specifications and requirements\u037e and\nall as updated, amended and revised from time to time by the Parties in writing in accordance with the terms of this Agreement,\nand in all cases including compliance with all Applicable Laws and the Quality Agreement\u037e\n\u201cQuality Agreement\u201d has the meaning specified in Section 2.6(a)\u037e\n\u201cRecall\u201d means any action (i) by AMAG to recover title to or possession of quantities of the Products, sample Products and/or\nTrainers sold or shipped to third parties (including, without limitation, the voluntary withdrawal of Products, sample Products\nand/or Trainers) from the market)\u037e or (ii) by any Regulatory Authorities to detain or destroy any of the Products and/or the sample\nProducts. Recall shall also include any action by either Party to refrain from selling or shipping quantities of the Products, sample\nProducts and/or Trainers to third parties which would have been subject to a Recall if sold or shipped\u037e\n\u201cSafety Stock\u201d has the meaning specified in Section 3.6(a)\u037e\n\u201cSecond Source Supplier\u201d has the meaning specified in Section 3.9\u037e\n\u201c[***]\u201d has the meaning specified in Section 2.1(b)\u037e\n\u201cSpecifications\u201d means the Product Specifications with respect to the Product and sample Product, and the Trainer\nSpecifications with respect to the Trainers, as the case may be\u037e\n\u201cSubcontractor\u201d has the meaning specified in Section 2.1(b)\u037e\n\u201cSupply Failure\u201d has the meaning specified in Section 3.5(a)\u037e\n\u201cSupply Failure Remedy Option\u201d has the meaning specified in Section 3.5(b)\u037e\n[***]\n\u201cTerm\u201d has the meaning specified in Section 7.1\u037e\n- 7 -\n"}, "__type__": "4"}, "55d06dca-b0a4-44fe-81c4-6de36ab5f3ef": {"__data__": {"id_": "55d06dca-b0a4-44fe-81c4-6de36ab5f3ef", "embedding": null, "metadata": {"page_label": "9", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n\u201c[***]\u201d has the meaning specified in Section 3.2(c)\u037e\n\u201cThird Person\u201d means any Person or entity other than AMAG, Antares, or an Affiliate or sublicensee of either Party with respect\nto this Agreement and/or the Development and License Agreement.\n\u201cThird Person Claim\u201d has the meaning specified in Section 9.1\u037e\n\u201cTrainer\u201d means a reusable version of the Product that does not incorporate the Prefilled Syringe and that is to be used to\ndemonstrate how to operate the Product\u037e\n\u201cTrainer Specifications\u201d means, as set forth on Exhibit C hereto, for each Trainer, the requirements and print/part numbers\ndocuments relating to such Trainer, as updated, amended and revised from time to time by or on behalf of the Parties, and in all\ncases including compliance with all Applicable Laws\u037e\n\u201cTransfer Price\u201d has the meaning specified on Exhibit D hereto\u037e\n\u201cU.S. GAAP\u201d has the meaning specified in the definition of Antares\u2019 Fully Burdened Manufacturing Costs\u037e and\n\u201cVAT\u201d means, in relation to any jurisdiction within the European Union, the value added tax provided for in Council Directive\n2006/112/EC and charged under the provisions of any national legislation implementing that directive or Council Directive\n77/388/EEC together with legislation supplemental thereto and, in relation to any other jurisdiction, the equivalent tax (if any) in\nthat jurisdiction.\n\u201cYield\u201d has the meaning specified in Section 2.10.\n1.2 Currency. Unless otherwise indicated, all monetary amounts are expressed in this Agreement in the lawful currency of the\nUnited States of America.\n1.3 Sections and Headings. The division of this Agreement into Articles, Sections, subsections and Exhibits and the insertion\nof headings are for convenience of reference only and shall not affect the interpretation of this Agreement. Unless otherwise\nindicated, any reference in this Agreement to an Article, Section or Exhibit refers to the specified Article, Section or Exhibit\nto this Agreement. In this Agreement, the terms \u201cthis Agreement\u201d, \u201chereof\u201d, \u201cherein\u201d, \u201chereunder\u201d and similar expressions\nrefer to this Agreement and not to any particular part, Section, Exhibit or the provision hereof.\n1.4 Singular Terms. Except as otherwise expressly provided herein or unless the context otherwise requires, all references to\nthe singular shall include the plural and vice versa.\n1.5 Exhibits. The following Exhibits are attached to, incorporated in and form part of this Agreement:\n- 8 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n\u201c[***]\u201d has the meaning specified in Section 3.2(c)\u037e\n\u201cThird Person\u201d means any Person or entity other than AMAG, Antares, or an Affiliate or sublicensee of either Party with respect\nto this Agreement and/or the Development and License Agreement.\n\u201cThird Person Claim\u201d has the meaning specified in Section 9.1\u037e\n\u201cTrainer\u201d means a reusable version of the Product that does not incorporate the Prefilled Syringe and that is to be used to\ndemonstrate how to operate the Product\u037e\n\u201cTrainer Specifications\u201d means, as set forth on Exhibit C hereto, for each Trainer, the requirements and print/part numbers\ndocuments relating to such Trainer, as updated, amended and revised from time to time by or on behalf of the Parties, and in all\ncases including compliance with all Applicable Laws\u037e\n\u201cTransfer Price\u201d has the meaning specified on Exhibit D hereto\u037e\n\u201cU.S. GAAP\u201d has the meaning specified in the definition of Antares\u2019 Fully Burdened Manufacturing Costs\u037e and\n\u201cVAT\u201d means, in relation to any jurisdiction within the European Union, the value added tax provided for in Council Directive\n2006/112/EC and charged under the provisions of any national legislation implementing that directive or Council Directive\n77/388/EEC together with legislation supplemental thereto and, in relation to any other jurisdiction, the equivalent tax (if any) in\nthat jurisdiction.\n\u201cYield\u201d has the meaning specified in Section 2.10.\n1.2 Currency. Unless otherwise indicated, all monetary amounts are expressed in this Agreement in the lawful currency of the\nUnited States of America.\n1.3 Sections and Headings. The division of this Agreement into Articles, Sections, subsections and Exhibits and the insertion\nof headings are for convenience of reference only and shall not affect the interpretation of this Agreement. Unless otherwise\nindicated, any reference in this Agreement to an Article, Section or Exhibit refers to the specified Article, Section or Exhibit\nto this Agreement. In this Agreement, the terms \u201cthis Agreement\u201d, \u201chereof\u201d, \u201cherein\u201d, \u201chereunder\u201d and similar expressions\nrefer to this Agreement and not to any particular part, Section, Exhibit or the provision hereof.\n1.4 Singular Terms. Except as otherwise expressly provided herein or unless the context otherwise requires, all references to\nthe singular shall include the plural and vice versa.\n1.5 Exhibits. The following Exhibits are attached to, incorporated in and form part of this Agreement:\n- 8 -\n"}, "__type__": "4"}, "bbd2446f-f033-470e-9e16-07cc043bb645": {"__data__": {"id_": "bbd2446f-f033-470e-9e16-07cc043bb645", "embedding": null, "metadata": {"page_label": "10", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nExhibit A - Long Lead Time Materials\nExhibit B - Product Specifications\nExhibit C - Trainer Specifications\nExhibit D - Transfer Price\nExhibit E - Quality Agreement\nExhibit F - Batch Numbering & Expiration Dates\nExhibit G - Retained Samples\nExhibit H - Initial Forecast\nExhibit I - Redundancy Plan\nExhibit J - [***]\nExhibit K - AMAG Equipment\nExhibit L - Form of Change Order\nARTICLE 2 \nMANUFACTURING AND SUPPLY OBLIGATIONS\n2.1 Manufacturing Services.\n(a) Starting on the Effective Date, Antares or its Subcontractor shall provide the Manufacturing Services in order to\nmanufacture Devices, Products, sample Products and Trainers exclusively for AMAG for the Territory, all in\naccordance with the Specifications, Applicable Laws, Quality Agreement and this Agreement. For the avoidance of\ndoubt, subject to, and without limiting or amending the exclusivity restrictions and confidentiality obligations set forth\nin Section 6.1 and ARTICLE 17 of the Development and License Agreement, respectively, Antares or its\nSubcontractor may manufacture the VIBEX\u00ae QS device or other devices (other than the Device) for itself or other\nPersons. Antares or its Subcontractor shall conduct all Manufacturing Services at the Manufacturing Site and may\nchange the Manufacturing Site for the Products, sample Products and Trainers only with the prior written consent of\nAMAG, such consent not to be unreasonably withheld, conditioned or delayed (provided that, Antares or its\nSubcontractor shall provide a minimum of [***] prior written notice of such change of Manufacturing Site).\n(b) [***].\n(c) Antares shall have the right to specify the final assembly packaging and labeling process (subject to AMAG\u2019s\nprovision of label content) for Products, sample Products and Trainers, including the combination of the components\nthereof, in accordance with the Specifications and the Quality Agreement.\n2.2 Prefilled Syringes.\n(a) AMAG or its designee(s) will be responsible for manufacture, formulation and testing of any Drug and the Prefilled\nSyringe for assembly with the Device into the Product\n- 9 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nExhibit A - Long Lead Time Materials\nExhibit B - Product Specifications\nExhibit C - Trainer Specifications\nExhibit D - Transfer Price\nExhibit E - Quality Agreement\nExhibit F - Batch Numbering & Expiration Dates\nExhibit G - Retained Samples\nExhibit H - Initial Forecast\nExhibit I - Redundancy Plan\nExhibit J - [***]\nExhibit K - AMAG Equipment\nExhibit L - Form of Change Order\nARTICLE 2 \nMANUFACTURING AND SUPPLY OBLIGATIONS\n2.1 Manufacturing Services.\n(a) Starting on the Effective Date, Antares or its Subcontractor shall provide the Manufacturing Services in order to\nmanufacture Devices, Products, sample Products and Trainers exclusively for AMAG for the Territory, all in\naccordance with the Specifications, Applicable Laws, Quality Agreement and this Agreement. For the avoidance of\ndoubt, subject to, and without limiting or amending the exclusivity restrictions and confidentiality obligations set forth\nin Section 6.1 and ARTICLE 17 of the Development and License Agreement, respectively, Antares or its\nSubcontractor may manufacture the VIBEX\u00ae QS device or other devices (other than the Device) for itself or other\nPersons. Antares or its Subcontractor shall conduct all Manufacturing Services at the Manufacturing Site and may\nchange the Manufacturing Site for the Products, sample Products and Trainers only with the prior written consent of\nAMAG, such consent not to be unreasonably withheld, conditioned or delayed (provided that, Antares or its\nSubcontractor shall provide a minimum of [***] prior written notice of such change of Manufacturing Site).\n(b) [***].\n(c) Antares shall have the right to specify the final assembly packaging and labeling process (subject to AMAG\u2019s\nprovision of label content) for Products, sample Products and Trainers, including the combination of the components\nthereof, in accordance with the Specifications and the Quality Agreement.\n2.2 Prefilled Syringes.\n(a) AMAG or its designee(s) will be responsible for manufacture, formulation and testing of any Drug and the Prefilled\nSyringe for assembly with the Device into the Product\n- 9 -\n"}, "__type__": "4"}, "ecad764f-1548-409b-8119-f302fa9fb8a4": {"__data__": {"id_": "ecad764f-1548-409b-8119-f302fa9fb8a4", "embedding": null, "metadata": {"page_label": "11", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nand sample Product by Antares or its Subcontractor and for final Product and/or sample Product release for sale,\ncommercialization or use by a Third Person. AMAG shall supply Prefilled Syringes to Antares or its Subcontractor in accordance\nwith the terms of this Section 2.2 AMAG will have sole decision-making authority regarding the use of a Third Person to\nmanufacture any aspect of the Drug and the Prefilled Syringes. AMAG shall conduct release testing for Prefilled Syringes. Antares\nor its Subcontractor shall use and store all Prefilled Syringes provided hereunder in accordance with AMAG\u2019s reasonable\ninstructions, the Quality Agreement, cGMPs and all other Applicable Laws at Antares\u2019 or its Subcontractor\u2019s storage facility at the\nManufacturing Site. Antares or its Subcontractor shall conduct a visual inspection of all Prefilled Syringes received at the\nManufacturing Site not later than [***] after the date of receipt in accordance with the mutually agreed upon procedures. Antares\nor its Subcontractor shall promptly (and in any event within [***] following completion of applicable inspection) notify AMAG in\nwriting of any visual inspection failure of the Prefilled Syringes. Antares shall not allow any lien or other security interest to be\nimposed on the Prefilled Syringes by Antares or its Subcontractor or as a result of Antares or its Subcontractor action or inaction.\nAntares or its Subcontractor shall use all quantities of Prefilled Syringes provided hereunder for the sole purpose of performing the\nManufacturing Services on behalf of AMAG and not for any other use or purpose.\n(b) The Parties acknowledge and agree that title to and risk of loss of all Prefilled Syringes shall at all times belong to\nand remain in AMAG\u037e provided that, subject to the limitations on liability set forth in this Section 2.2(b), in the event\nof loss or damage of any Prefilled Syringes while they are at the Manufacturing Site, Antares shall be only\nresponsible for the replacement costs (as evidenced by AMAG invoices) of such Prefilled Syringes if the damage,\nloss, theft or destruction was caused by the negligent act or omission or the willful misconduct of Antares or its\nSubcontractor. For the avoidance of doubt, Antares shall not be responsible for any damage, loss or destruction to\nthe Prefilled Syringes resulting from damage, loss or destruction caused by the reasonable amount of Prefilled\nSyringes damaged, lost or destroyed in the manufacturing process (i.e. consistent with the Yield) or obsolescence\ndue to changes in the manufacturing process. Not later than [***] following the end of each Calendar Year, AMAG\nshall provide Antares with an invoice and accounting of the Prefilled Syringes that were damaged or destroyed\nduring the prior year (following notification from Antares of such damage or destruction). Payment of undisputed\nportions of such invoice shall be due [***] from Antares\u2019 receipt of such invoice. [***]. All Prefilled Syringes in\nAntares\u2019 possession shall be subject to disposition by AMAG upon expiration or termination of this Agreement, and\nin either such event, Antares or its Subcontractor shall deliver the Prefilled Syringes to AMAG or its designee, at\nAMAG\u2019s\n- 10 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nand sample Product by Antares or its Subcontractor and for final Product and/or sample Product release for sale,\ncommercialization or use by a Third Person. AMAG shall supply Prefilled Syringes to Antares or its Subcontractor in accordance\nwith the terms of this Section 2.2 AMAG will have sole decision-making authority regarding the use of a Third Person to\nmanufacture any aspect of the Drug and the Prefilled Syringes. AMAG shall conduct release testing for Prefilled Syringes. Antares\nor its Subcontractor shall use and store all Prefilled Syringes provided hereunder in accordance with AMAG\u2019s reasonable\ninstructions, the Quality Agreement, cGMPs and all other Applicable Laws at Antares\u2019 or its Subcontractor\u2019s storage facility at the\nManufacturing Site. Antares or its Subcontractor shall conduct a visual inspection of all Prefilled Syringes received at the\nManufacturing Site not later than [***] after the date of receipt in accordance with the mutually agreed upon procedures. Antares\nor its Subcontractor shall promptly (and in any event within [***] following completion of applicable inspection) notify AMAG in\nwriting of any visual inspection failure of the Prefilled Syringes. Antares shall not allow any lien or other security interest to be\nimposed on the Prefilled Syringes by Antares or its Subcontractor or as a result of Antares or its Subcontractor action or inaction.\nAntares or its Subcontractor shall use all quantities of Prefilled Syringes provided hereunder for the sole purpose of performing the\nManufacturing Services on behalf of AMAG and not for any other use or purpose.\n(b) The Parties acknowledge and agree that title to and risk of loss of all Prefilled Syringes shall at all times belong to\nand remain in AMAG\u037e provided that, subject to the limitations on liability set forth in this Section 2.2(b), in the event\nof loss or damage of any Prefilled Syringes while they are at the Manufacturing Site, Antares shall be only\nresponsible for the replacement costs (as evidenced by AMAG invoices) of such Prefilled Syringes if the damage,\nloss, theft or destruction was caused by the negligent act or omission or the willful misconduct of Antares or its\nSubcontractor. For the avoidance of doubt, Antares shall not be responsible for any damage, loss or destruction to\nthe Prefilled Syringes resulting from damage, loss or destruction caused by the reasonable amount of Prefilled\nSyringes damaged, lost or destroyed in the manufacturing process (i.e. consistent with the Yield) or obsolescence\ndue to changes in the manufacturing process. Not later than [***] following the end of each Calendar Year, AMAG\nshall provide Antares with an invoice and accounting of the Prefilled Syringes that were damaged or destroyed\nduring the prior year (following notification from Antares of such damage or destruction). Payment of undisputed\nportions of such invoice shall be due [***] from Antares\u2019 receipt of such invoice. [***]. All Prefilled Syringes in\nAntares\u2019 possession shall be subject to disposition by AMAG upon expiration or termination of this Agreement, and\nin either such event, Antares or its Subcontractor shall deliver the Prefilled Syringes to AMAG or its designee, at\nAMAG\u2019s\n- 10 -\n"}, "__type__": "4"}, "0cf1d310-a344-4bed-81c6-d4fa859c4005": {"__data__": {"id_": "0cf1d310-a344-4bed-81c6-d4fa859c4005", "embedding": null, "metadata": {"page_label": "12", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nreasonable expense. AMAG shall be solely responsible and reimburse Antares for all reasonable costs and expenses associated\nwith the storage of the Prefilled Syringes at Antares\u2019 or its Subcontractor\u2019s storage facility at the Manufacturing Site following the\nexpiration or termination of this Agreement. Antares agrees to reasonably cooperate with AMAG, at AMAG\u2019s expense, in the\nfiling of any UCC financing statements relating to the Prefilled Syringes as may be required under Applicable Laws.\n(c) All shipments of Prefilled Syringes made by AMAG or its designee to Antares or its Subcontractor hereunder will be\ndelivered [***] Antares\u2019 or its Subcontractor\u2019s Manufacturing Site unless otherwise mutually agreed. [***].\n2.3 Devices . Antares or its Subcontractor shall manufacture and test all Devices as specified by the Product Specifications\nprior to using such Devices to manufacture Products and sample Products. Antares or its Subcontractor shall properly\nstore the Devices at Antares\u2019 or its Subcontractor\u2019s storage facility at the Manufacturing Site pursuant to cGMP and\nApplicable Law.\n2.4 Components. Antares or its Subcontractor shall purchase and inspect all Components as specified by the Specifications\nprior to using such Components to manufacture Products, sample Products and Trainers. Antares or its Subcontractor\nshall properly store the Components at Antares\u2019 or its Subcontractor\u2019s storage facility at the Manufacturing Site pursuant\nto cGMP and Applicable Law.\n2.5 Assembly of Devices, Prefilled Syringes and Components . Antares or its Subcontractor shall assemble Devices,\nPrefilled Syringes and Components into Products, sample Products and Trainers (as applicable) in accordance with the\nterms of this Agreement.\n2.6 Quality Control and Quality Assurance.\n(a) On or about the date hereof, the Parties shall amend and restate the Quality Agreement entered into on May 16,\n2016 between the Parties covering the Product, sample Products, Trainers, the Device and the Prefilled Syringes, as\nset forth in the form of Amended and Restated Quality Agreement attached hereto as Exhibit E (as amended and\nrestated, the \u201cQuality Agreement\u201d). The Parties shall review the Quality Agreement and shall modify the same\nfrom time to time as detailed in the Quality Agreement as necessary through a written amendment to the Quality\nAgreement signed by an authorized representative on behalf of each of the Parties. The Parties shall perform the\nquality control and quality assurance testing specified in Section 2.6(b) and the Quality Agreement. The Parties shall\nperform Product, sample Product and Trainer review and final release of the Product, sample Product and Trainers\nfor sale in accordance with Section 2.6(b) and the Quality Agreement, the Specifications and Applicable Laws.\n- 11 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nreasonable expense. AMAG shall be solely responsible and reimburse Antares for all reasonable costs and expenses associated\nwith the storage of the Prefilled Syringes at Antares\u2019 or its Subcontractor\u2019s storage facility at the Manufacturing Site following the\nexpiration or termination of this Agreement. Antares agrees to reasonably cooperate with AMAG, at AMAG\u2019s expense, in the\nfiling of any UCC financing statements relating to the Prefilled Syringes as may be required under Applicable Laws.\n(c) All shipments of Prefilled Syringes made by AMAG or its designee to Antares or its Subcontractor hereunder will be\ndelivered [***] Antares\u2019 or its Subcontractor\u2019s Manufacturing Site unless otherwise mutually agreed. [***].\n2.3 Devices . Antares or its Subcontractor shall manufacture and test all Devices as specified by the Product Specifications\nprior to using such Devices to manufacture Products and sample Products. Antares or its Subcontractor shall properly\nstore the Devices at Antares\u2019 or its Subcontractor\u2019s storage facility at the Manufacturing Site pursuant to cGMP and\nApplicable Law.\n2.4 Components. Antares or its Subcontractor shall purchase and inspect all Components as specified by the Specifications\nprior to using such Components to manufacture Products, sample Products and Trainers. Antares or its Subcontractor\nshall properly store the Components at Antares\u2019 or its Subcontractor\u2019s storage facility at the Manufacturing Site pursuant\nto cGMP and Applicable Law.\n2.5 Assembly of Devices, Prefilled Syringes and Components . Antares or its Subcontractor shall assemble Devices,\nPrefilled Syringes and Components into Products, sample Products and Trainers (as applicable) in accordance with the\nterms of this Agreement.\n2.6 Quality Control and Quality Assurance.\n(a) On or about the date hereof, the Parties shall amend and restate the Quality Agreement entered into on May 16,\n2016 between the Parties covering the Product, sample Products, Trainers, the Device and the Prefilled Syringes, as\nset forth in the form of Amended and Restated Quality Agreement attached hereto as Exhibit E (as amended and\nrestated, the \u201cQuality Agreement\u201d). The Parties shall review the Quality Agreement and shall modify the same\nfrom time to time as detailed in the Quality Agreement as necessary through a written amendment to the Quality\nAgreement signed by an authorized representative on behalf of each of the Parties. The Parties shall perform the\nquality control and quality assurance testing specified in Section 2.6(b) and the Quality Agreement. The Parties shall\nperform Product, sample Product and Trainer review and final release of the Product, sample Product and Trainers\nfor sale in accordance with Section 2.6(b) and the Quality Agreement, the Specifications and Applicable Laws.\n- 11 -\n"}, "__type__": "4"}, "dff0578e-3119-404e-aa01-a44032763200": {"__data__": {"id_": "dff0578e-3119-404e-aa01-a44032763200", "embedding": null, "metadata": {"page_label": "13", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n(b) Subject to, and as more fully set forth in, the Quality Agreement, the Parties agree as follows:\n[***].\n2.7 Labelling and Packaging. Antares or its Subcontractor shall label and package the Products, sample Products and\nTrainers as set out in the Specifications. AMAG shall be responsible for the cost of artwork development for the Products,\nsample Products and Trainers. In addition, Antares or its Subcontractor shall arrange for and implement (a) the imprinting\nof batch numbers and expiration dates for each batch of Products and sample Products shipped, and (b) the imprinting of\nbatch numbers for each batch of Trainers shipped. Such batch numbers and expiration dates shall be affixed on the\nProducts, sample Products and Trainers and, on the shipping carton of each Product, sample Product and Trainer as\noutlined in the Specifications and, as required by cGMPs and Applicable Laws. The system used by Antares or its\nSubcontractor for batch numbering and expiration dates is detailed in Exhibit F hereto. AMAG shall be solely responsible\nfor the content of the labelling and the provision of such content. Notwithstanding anything to the contrary in this\nAgreement, Antares\u2019 obligation to perform the Manufacturing Services is subject to AMAG\u2019s reasonably timely approval\nand provision of all labelling content. AMAG may, in its sole discretion, make changes to labels, product inserts and other\npackaging for the Products, sample Products and Trainers, which changes shall be submitted by AMAG to all applicable\nRegulatory Authorities from which approval of such changes is required. AMAG shall be responsible for the cost of\nlabeling obsolescence due to changes to such labeling made by AMAG, including the reasonable cost of disposal and\nreplacement of packaging materials. Antares\u2019 name shall appear on the label or anywhere else on the Products, sample\nProducts and Trainers as reasonably agreed upon by the Parties, unless: (i) prohibited by Applicable Laws\u037e or (ii) the\nParties otherwise agree in writing.\n2.8 Validation Activities. Antares or its Subcontractor will be responsible for the development and approval of the validation\nprotocols for analytical methods and manufacturing processes (including packaging processes) for the Products, sample\nProducts and Trainers as described in the Specifications in accordance with the Quality Agreement and shall be approved\nby AMAG prior to execution thereof. [***].\n2.9 Retained Samples. Antares or its Subcontractor shall retain sufficient quantities of shipped Products, sample Products,\nDevices and Components as retained repository samples as required under the Quality Agreement and Applicable Laws at\nAMAG\u2019s sole cost and expense and as set forth in Exhibit G. Such retained samples shall minimally represent [***] the\nnumber of samples necessary to re-execute chemical release testing and will be maintained in a suitable storage facility at\nAntares\u2019 or its Subcontractors\u2019 Manufacturing Site until [***] or such longer period as may be required by Applicable\nLaws. All such samples shall be available for inspection by AMAG at reasonable intervals upon reasonable\n- 12 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n(b) Subject to, and as more fully set forth in, the Quality Agreement, the Parties agree as follows:\n[***].\n2.7 Labelling and Packaging. Antares or its Subcontractor shall label and package the Products, sample Products and\nTrainers as set out in the Specifications. AMAG shall be responsible for the cost of artwork development for the Products,\nsample Products and Trainers. In addition, Antares or its Subcontractor shall arrange for and implement (a) the imprinting\nof batch numbers and expiration dates for each batch of Products and sample Products shipped, and (b) the imprinting of\nbatch numbers for each batch of Trainers shipped. Such batch numbers and expiration dates shall be affixed on the\nProducts, sample Products and Trainers and, on the shipping carton of each Product, sample Product and Trainer as\noutlined in the Specifications and, as required by cGMPs and Applicable Laws. The system used by Antares or its\nSubcontractor for batch numbering and expiration dates is detailed in Exhibit F hereto. AMAG shall be solely responsible\nfor the content of the labelling and the provision of such content. Notwithstanding anything to the contrary in this\nAgreement, Antares\u2019 obligation to perform the Manufacturing Services is subject to AMAG\u2019s reasonably timely approval\nand provision of all labelling content. AMAG may, in its sole discretion, make changes to labels, product inserts and other\npackaging for the Products, sample Products and Trainers, which changes shall be submitted by AMAG to all applicable\nRegulatory Authorities from which approval of such changes is required. AMAG shall be responsible for the cost of\nlabeling obsolescence due to changes to such labeling made by AMAG, including the reasonable cost of disposal and\nreplacement of packaging materials. Antares\u2019 name shall appear on the label or anywhere else on the Products, sample\nProducts and Trainers as reasonably agreed upon by the Parties, unless: (i) prohibited by Applicable Laws\u037e or (ii) the\nParties otherwise agree in writing.\n2.8 Validation Activities. Antares or its Subcontractor will be responsible for the development and approval of the validation\nprotocols for analytical methods and manufacturing processes (including packaging processes) for the Products, sample\nProducts and Trainers as described in the Specifications in accordance with the Quality Agreement and shall be approved\nby AMAG prior to execution thereof. [***].\n2.9 Retained Samples. Antares or its Subcontractor shall retain sufficient quantities of shipped Products, sample Products,\nDevices and Components as retained repository samples as required under the Quality Agreement and Applicable Laws at\nAMAG\u2019s sole cost and expense and as set forth in Exhibit G. Such retained samples shall minimally represent [***] the\nnumber of samples necessary to re-execute chemical release testing and will be maintained in a suitable storage facility at\nAntares\u2019 or its Subcontractors\u2019 Manufacturing Site until [***] or such longer period as may be required by Applicable\nLaws. All such samples shall be available for inspection by AMAG at reasonable intervals upon reasonable\n- 12 -\n"}, "__type__": "4"}, "c777efec-389f-48b3-b95c-048455221178": {"__data__": {"id_": "c777efec-389f-48b3-b95c-048455221178", "embedding": null, "metadata": {"page_label": "14", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nnotice. AMAG shall advise Antares of the required quantities of shipped Products, sample Products, Devices and Components\nthat AMAG desires to be retained. Antares shall invoice AMAG for the costs associated with performing these activities.\n2.10 Yield. [***].\nARTICLE 3 \nANTARES\u2019 SUPPLY OF PRODUCT\n3.1 Supply of Product.\n(a) Commencing on the Effective Date and continuing during the Term, Antares shall manufacture and supply, or have\nmanufactured and supplied by its Subcontractor, all quantities of the Products, sample Products and Trainers\nordered by AMAG in the Territory pursuant to this Agreement. Commencing on the Effective Date and during the\nTerm, AMAG shall commit to purchase its entire requirements of Product(s), sample Products and Trainers for sale\nin the Territory from Antares.\n(b) The Parties agree that in the event that AMAG seeks Regulatory Approval for the Product, sample Product or\nTrainers for a country outside of the United States, the Parties will enter into an amendment to this Agreement setting\nforth the terms and conditions of supply of Products, sample Products or Trainers for that country.\n3.2 Orders and Forecasts.\n(a) Rolling Forecasts. On or before the [***] after the Effective Date, AMAG shall provide Antares with an updated\nwritten [***] rolling forecast of the volume of Product, sample Product and Trainers that AMAG then anticipates\nwill be required to be produced and delivered to AMAG during [***] (the \u201c Forecast\u201d). The initial Forecast is\nattached hereto as Exhibit H. [***] of each Forecast shall constitute a firm order and be a binding commitment on\nAMAG to purchase the volume of Product, sample Product and Trainers set forth therein (the \u201cBinding Forecast\u201d).\n[***] of each Forecast shall be non-binding (the \u201cNon-binding Forecast\u201d). The Non-binding Forecast shall be\nprepared in good faith by AMAG and represent AMAG\u2019s reasonable expectation of its requirements of Product,\nsample Product and Trainers for [***] of such Forecast. Each Forecast shall include an estimated delivery date of\nthe Prefilled Syringes to Antares or its Subcontractor (such estimate to be provided by AMAG in good faith).\n(b) Purchase Orders.\n(i) To order Products, sample Products and Trainers for supply by Antares or its Subcontractor under this\nAgreement, AMAG shall submit to Antares a Purchase Order (which is deemed binding on AMAG)\ncomplying with the other applicable terms of this Agreement [***]. Not later than [***] after receipt of a\nPurchase\n- 13 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nnotice. AMAG shall advise Antares of the required quantities of shipped Products, sample Products, Devices and Components\nthat AMAG desires to be retained. Antares shall invoice AMAG for the costs associated with performing these activities.\n2.10 Yield. [***].\nARTICLE 3 \nANTARES\u2019 SUPPLY OF PRODUCT\n3.1 Supply of Product.\n(a) Commencing on the Effective Date and continuing during the Term, Antares shall manufacture and supply, or have\nmanufactured and supplied by its Subcontractor, all quantities of the Products, sample Products and Trainers\nordered by AMAG in the Territory pursuant to this Agreement. Commencing on the Effective Date and during the\nTerm, AMAG shall commit to purchase its entire requirements of Product(s), sample Products and Trainers for sale\nin the Territory from Antares.\n(b) The Parties agree that in the event that AMAG seeks Regulatory Approval for the Product, sample Product or\nTrainers for a country outside of the United States, the Parties will enter into an amendment to this Agreement setting\nforth the terms and conditions of supply of Products, sample Products or Trainers for that country.\n3.2 Orders and Forecasts.\n(a) Rolling Forecasts. On or before the [***] after the Effective Date, AMAG shall provide Antares with an updated\nwritten [***] rolling forecast of the volume of Product, sample Product and Trainers that AMAG then anticipates\nwill be required to be produced and delivered to AMAG during [***] (the \u201c Forecast\u201d). The initial Forecast is\nattached hereto as Exhibit H. [***] of each Forecast shall constitute a firm order and be a binding commitment on\nAMAG to purchase the volume of Product, sample Product and Trainers set forth therein (the \u201cBinding Forecast\u201d).\n[***] of each Forecast shall be non-binding (the \u201cNon-binding Forecast\u201d). The Non-binding Forecast shall be\nprepared in good faith by AMAG and represent AMAG\u2019s reasonable expectation of its requirements of Product,\nsample Product and Trainers for [***] of such Forecast. Each Forecast shall include an estimated delivery date of\nthe Prefilled Syringes to Antares or its Subcontractor (such estimate to be provided by AMAG in good faith).\n(b) Purchase Orders.\n(i) To order Products, sample Products and Trainers for supply by Antares or its Subcontractor under this\nAgreement, AMAG shall submit to Antares a Purchase Order (which is deemed binding on AMAG)\ncomplying with the other applicable terms of this Agreement [***]. Not later than [***] after receipt of a\nPurchase\n- 13 -\n"}, "__type__": "4"}, "ab447eb3-fd4d-4fd3-8ce9-b3c691e45cc8": {"__data__": {"id_": "ab447eb3-fd4d-4fd3-8ce9-b3c691e45cc8", "embedding": null, "metadata": {"page_label": "15", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nOrder, Antares shall confirm in writing its receipt of the Purchase Order (\u201cOrder Acceptance\u201d) and the proposed delivery date\nto AMAG in writing\u037e provided that Antares may reject any Purchase Order not consistent with the requirements set forth in this\nAgreement, including this Section 3.2(b)(i). AMAG shall notify Antares within [***] after receipt of the Order Acceptance if such\nproposed delivery date is unacceptable for AMAG, and in such event, the Parties shall promptly discuss and seek to agree on an\nalternative delivery date. If AMAG does not respond within such [***] period, the proposed date will be the confirmed delivery\ndate. Antares shall not be obligated to fill any portion of any Purchase Order to the extent the volumes in such Purchase Order\nexceed the volumes set forth in the most recent Binding Forecast (such excess amount, the \u201cExcess Order\u201d). For any Purchase\nOrder that contains an Excess Order, Antares shall notify AMAG in the Order Acceptance whether Antares and/or its\nSubcontractors will fulfill such Excess Order (or part thereof) and the expected delivery date for fulfillment. The decision to fulfill\nany Excess Order may be made by Antares in its sole discretion and Antares shall not be liable for any failure to deliver any\nProduct, sample Product or Trainers set forth in any Excess Order\u037e provided that Antares meets its obligations consistent with the\nBinding Forecast. AMAG\u2019s failure to deliver a Purchase Order consistent with the volumes of Product, sample Product and/or\nTrainers under any Binding Forecast, shall not relieve AMAG of its obligation to purchase such volumes of Product, sample\nProduct and/or Trainers. The terms of this Agreement shall be controlling and any additional or inconsistent terms or conditions\ncontained on any Forecast, Purchase Order, Order Acceptance, invoice or similar documentation given or received by the Parties\nshall have no effect and such terms and conditions are expressly disclaimed and excluded.\n(ii) AMAG and Antares acknowledge and agree that any minor difference between the quantity of ordered and\ndelivered quantity of Product, sample Product or Trainers (as the case may be) that falls within applicable\nindustry standards shall be accepted by AMAG as delivery in full of the ordered quantities set forth on any\nFirm Order and shall not be deemed a shortage as set forth in Section 5.1(c), but in no event shall the quantity\ndelivered deviate from the quantity ordered by more than: [***].\n(iii) Notwithstanding anything in this Agreement to the contrary, AMAG acknowledges and agrees that Antares\nshall only be responsible for producing and delivering to AMAG that portion (up to the entire quantity) of\nProducts and sample Products requested pursuant to a Purchase Order for which Antares or its Subcontractor\n(as the case may be) possesses, at least [***] prior to the Delivery Date, a sufficient stock of inventory of\nPrefilled Syringes necessary to\n- 14 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nOrder, Antares shall confirm in writing its receipt of the Purchase Order (\u201cOrder Acceptance\u201d) and the proposed delivery date\nto AMAG in writing\u037e provided that Antares may reject any Purchase Order not consistent with the requirements set forth in this\nAgreement, including this Section 3.2(b)(i). AMAG shall notify Antares within [***] after receipt of the Order Acceptance if such\nproposed delivery date is unacceptable for AMAG, and in such event, the Parties shall promptly discuss and seek to agree on an\nalternative delivery date. If AMAG does not respond within such [***] period, the proposed date will be the confirmed delivery\ndate. Antares shall not be obligated to fill any portion of any Purchase Order to the extent the volumes in such Purchase Order\nexceed the volumes set forth in the most recent Binding Forecast (such excess amount, the \u201cExcess Order\u201d). For any Purchase\nOrder that contains an Excess Order, Antares shall notify AMAG in the Order Acceptance whether Antares and/or its\nSubcontractors will fulfill such Excess Order (or part thereof) and the expected delivery date for fulfillment. The decision to fulfill\nany Excess Order may be made by Antares in its sole discretion and Antares shall not be liable for any failure to deliver any\nProduct, sample Product or Trainers set forth in any Excess Order\u037e provided that Antares meets its obligations consistent with the\nBinding Forecast. AMAG\u2019s failure to deliver a Purchase Order consistent with the volumes of Product, sample Product and/or\nTrainers under any Binding Forecast, shall not relieve AMAG of its obligation to purchase such volumes of Product, sample\nProduct and/or Trainers. The terms of this Agreement shall be controlling and any additional or inconsistent terms or conditions\ncontained on any Forecast, Purchase Order, Order Acceptance, invoice or similar documentation given or received by the Parties\nshall have no effect and such terms and conditions are expressly disclaimed and excluded.\n(ii) AMAG and Antares acknowledge and agree that any minor difference between the quantity of ordered and\ndelivered quantity of Product, sample Product or Trainers (as the case may be) that falls within applicable\nindustry standards shall be accepted by AMAG as delivery in full of the ordered quantities set forth on any\nFirm Order and shall not be deemed a shortage as set forth in Section 5.1(c), but in no event shall the quantity\ndelivered deviate from the quantity ordered by more than: [***].\n(iii) Notwithstanding anything in this Agreement to the contrary, AMAG acknowledges and agrees that Antares\nshall only be responsible for producing and delivering to AMAG that portion (up to the entire quantity) of\nProducts and sample Products requested pursuant to a Purchase Order for which Antares or its Subcontractor\n(as the case may be) possesses, at least [***] prior to the Delivery Date, a sufficient stock of inventory of\nPrefilled Syringes necessary to\n- 14 -\n"}, "__type__": "4"}, "d5cc2269-0675-4fff-afb2-57f439132826": {"__data__": {"id_": "d5cc2269-0675-4fff-afb2-57f439132826", "embedding": null, "metadata": {"page_label": "16", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nfulfill such order (including any additional quantity of Prefilled Syringes necessary to account for Prefilled Syringes reasonably\nexpected to be damaged, lost or destroyed in the manufacturing process (i.e. consistent with the Yield)) and the Certificate of\nAnalysis (PFS Manufacture) relating thereto. In the event that Antares or its Subcontractor (as the case may be) has not received\na sufficient stock of Prefilled Syringes by the dates set forth in the previous sentence, Antares or its Subcontractor shall (A)\nmanufacture and deliver such number of Products and sample Products for which Antares or its Subcontractor (as the case may\nbe) has Prefilled Syringes in accordance with the schedule set forth in the Firm Order, and (B) as soon as practicable (and no\nmore than [***] following receipt of the Prefilled Syringes required for such Firm Order, Antares or its Subcontractor shall\nmanufacture and deliver the Products and sample Products in such order taking into account any Products and sample Products\nmanufactured and delivered pursuant to subsection (A).\n(iv) Notwithstanding anything in this Agreement to the contrary, AMAG acknowledges and agrees that Antares\nshall not be responsible for delay in the delivery of quantity of Products, sample Products or Trainers (as the\ncase may be) set forth in any Firm Order to the extent such delay is caused primarily due to AMAG\u2019s failure to\nfulfill the AMAG Quality Tasks to enable Antares and/or its Subcontractor to timely perform the\nManufacturing Services.\n(c) Prior Orders. [***].\n3.3 Minimum Orders. The quantity of Products, sample Products or Trainers (as the case may be) ordered by AMAG from\nAntares in each shipment (as set forth in a Purchase Order) must be equal to or greater than [***] units for each type of\nProduct, sample Product and Trainers ordered. Such minimum order quantity may be updated from time to time by a\nmutual written agreement of the Parties. For avoidance of doubt, except for any Purchase Orders placed by AMAG\nand/or quantities set forth in the Binding Forecast, nothing in this Agreement requires AMAG to purchase any particular\nquantity of Products from Antares.\n3.4 Shipments.\n(a) Shipments of Products, sample Product and Trainers shall be made EXW (as such term is defined in INCOTERMS\n2010) Antares\u2019 or its Subcontractor\u2019s (as the case may be) designated shipping location unless otherwise mutually\nagreed. The Parties acknowledge and agree that delivery of Products, samples Products and/or Trainers under this\nAgreement shall be deemed to be made once the Products, samples Products and/or Trainers (as the case may be)\nare made available at Antares\u2019 or its Subcontractor\u2019s (as the case may be) designated shipping location. [***].\nAMAG shall pay for shipping. AMAG shall arrange for insurance and shall select the freight\n- 15 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nfulfill such order (including any additional quantity of Prefilled Syringes necessary to account for Prefilled Syringes reasonably\nexpected to be damaged, lost or destroyed in the manufacturing process (i.e. consistent with the Yield)) and the Certificate of\nAnalysis (PFS Manufacture) relating thereto. In the event that Antares or its Subcontractor (as the case may be) has not received\na sufficient stock of Prefilled Syringes by the dates set forth in the previous sentence, Antares or its Subcontractor shall (A)\nmanufacture and deliver such number of Products and sample Products for which Antares or its Subcontractor (as the case may\nbe) has Prefilled Syringes in accordance with the schedule set forth in the Firm Order, and (B) as soon as practicable (and no\nmore than [***] following receipt of the Prefilled Syringes required for such Firm Order, Antares or its Subcontractor shall\nmanufacture and deliver the Products and sample Products in such order taking into account any Products and sample Products\nmanufactured and delivered pursuant to subsection (A).\n(iv) Notwithstanding anything in this Agreement to the contrary, AMAG acknowledges and agrees that Antares\nshall not be responsible for delay in the delivery of quantity of Products, sample Products or Trainers (as the\ncase may be) set forth in any Firm Order to the extent such delay is caused primarily due to AMAG\u2019s failure to\nfulfill the AMAG Quality Tasks to enable Antares and/or its Subcontractor to timely perform the\nManufacturing Services.\n(c) Prior Orders. [***].\n3.3 Minimum Orders. The quantity of Products, sample Products or Trainers (as the case may be) ordered by AMAG from\nAntares in each shipment (as set forth in a Purchase Order) must be equal to or greater than [***] units for each type of\nProduct, sample Product and Trainers ordered. Such minimum order quantity may be updated from time to time by a\nmutual written agreement of the Parties. For avoidance of doubt, except for any Purchase Orders placed by AMAG\nand/or quantities set forth in the Binding Forecast, nothing in this Agreement requires AMAG to purchase any particular\nquantity of Products from Antares.\n3.4 Shipments.\n(a) Shipments of Products, sample Product and Trainers shall be made EXW (as such term is defined in INCOTERMS\n2010) Antares\u2019 or its Subcontractor\u2019s (as the case may be) designated shipping location unless otherwise mutually\nagreed. The Parties acknowledge and agree that delivery of Products, samples Products and/or Trainers under this\nAgreement shall be deemed to be made once the Products, samples Products and/or Trainers (as the case may be)\nare made available at Antares\u2019 or its Subcontractor\u2019s (as the case may be) designated shipping location. [***].\nAMAG shall pay for shipping. AMAG shall arrange for insurance and shall select the freight\n- 15 -\n"}, "__type__": "4"}, "de01b267-2b71-41f4-a82a-dbda4bd63e39": {"__data__": {"id_": "de01b267-2b71-41f4-a82a-dbda4bd63e39", "embedding": null, "metadata": {"page_label": "17", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\ncarrier to ship Products, sample Products and Trainers. Antares shall not be responsible for the payment of such insurance.\nProducts, sample Products and Trainers shall be transported in accordance with the Specifications.\n(b) Prior to release for distribution, sale or use by AMAG pursuant to Section 2.6(b)(v)(D), AMAG, its agent or its\npermitted subcontractor shall test each batch of Products, sample Products and Trainers manufactured under this\nAgreement in accordance with Section 2.6(b)(v)(D). AMAG, its agent or its permitted subcontractor shall conduct\nall such testing in accordance with the procedures and using the analytical testing methodologies set forth in the\nSpecifications, the Quality Agreement and Applicable Laws. All Products, sample Products and Trainers shipped by\nAntares or its Subcontractor to AMAG or AMAG\u2019s designee, including its packaging, shall meet all applicable\nexport and customs laws, regulations and like requirements for the United States.\n3.5 Supply Failure.\n[***].\n3.6 Safety Stock.\n(a) At AMAG\u2019s sole cost and expense, Antares or its Subcontractor will maintain and make available to AMAG a\nsafety inventory of the Major Device Components necessary to assemble the Devices in the quantities set forth in this\nSection 3.6(a) at Antares or its Subcontractor\u2019s Manufacturing Site in accordance with this Section 3.6 (\u201cSafety\nStock\u201d).\n(i) [***].\n(ii) [***].\n(b) With respect to the initial Safety Stock (as set forth in Section 3.6(a)(i)) or any increase in Safety Stock pursuant to\nSection 3.6(a)(ii), upon the completion of the manufacture of such Safety Stock and delivery to AMAG of the\nCertificate of Analysis (Device) and the Certificate of Conformance (Device) applicable to such Safety Stock,\nAntares shall invoice AMAG for its [***] pursuant to invoicing and payment terms set forth in Section 4.2.\n(c) With respect to any reduction in the Safety Stock pursuant to Sections 3.6(a)(ii) or 3.6(d), to the extent such\nreduced quantities of Safety Stock are used in the manufacture of fully finished Products and/or sample Products,\nthen Antares shall credit any amount previously paid by AMAG with respect to such reduced quantity in Safety\nStock in the Invoice issued to AMAG pursuant to Section 4.2 for such fully finished Product and/or sample Product.\n- 16 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\ncarrier to ship Products, sample Products and Trainers. Antares shall not be responsible for the payment of such insurance.\nProducts, sample Products and Trainers shall be transported in accordance with the Specifications.\n(b) Prior to release for distribution, sale or use by AMAG pursuant to Section 2.6(b)(v)(D), AMAG, its agent or its\npermitted subcontractor shall test each batch of Products, sample Products and Trainers manufactured under this\nAgreement in accordance with Section 2.6(b)(v)(D). AMAG, its agent or its permitted subcontractor shall conduct\nall such testing in accordance with the procedures and using the analytical testing methodologies set forth in the\nSpecifications, the Quality Agreement and Applicable Laws. All Products, sample Products and Trainers shipped by\nAntares or its Subcontractor to AMAG or AMAG\u2019s designee, including its packaging, shall meet all applicable\nexport and customs laws, regulations and like requirements for the United States.\n3.5 Supply Failure.\n[***].\n3.6 Safety Stock.\n(a) At AMAG\u2019s sole cost and expense, Antares or its Subcontractor will maintain and make available to AMAG a\nsafety inventory of the Major Device Components necessary to assemble the Devices in the quantities set forth in this\nSection 3.6(a) at Antares or its Subcontractor\u2019s Manufacturing Site in accordance with this Section 3.6 (\u201cSafety\nStock\u201d).\n(i) [***].\n(ii) [***].\n(b) With respect to the initial Safety Stock (as set forth in Section 3.6(a)(i)) or any increase in Safety Stock pursuant to\nSection 3.6(a)(ii), upon the completion of the manufacture of such Safety Stock and delivery to AMAG of the\nCertificate of Analysis (Device) and the Certificate of Conformance (Device) applicable to such Safety Stock,\nAntares shall invoice AMAG for its [***] pursuant to invoicing and payment terms set forth in Section 4.2.\n(c) With respect to any reduction in the Safety Stock pursuant to Sections 3.6(a)(ii) or 3.6(d), to the extent such\nreduced quantities of Safety Stock are used in the manufacture of fully finished Products and/or sample Products,\nthen Antares shall credit any amount previously paid by AMAG with respect to such reduced quantity in Safety\nStock in the Invoice issued to AMAG pursuant to Section 4.2 for such fully finished Product and/or sample Product.\n- 16 -\n"}, "__type__": "4"}, "b2f47ca2-e351-4963-ba66-4775b64b4c9b": {"__data__": {"id_": "b2f47ca2-e351-4963-ba66-4775b64b4c9b", "embedding": null, "metadata": {"page_label": "18", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n(d) Antares or its Subcontractor shall manage the Safety Stock as part of its overall inventory and use the Safety Stock\nto fulfill its obligations pursuant to a Firm Orders on a first in/first out basis. As such inventory of Safety Stock is used\nas part of the Manufacturing Services of Product and/or sample Product, Antares shall use Commercially\nReasonable Efforts to replenish the Safety Stock to the level set forth in Section 3.6(a)(i) (as adjusted pursuant to\nSection 3.6(a)(ii)) within [***] of receipt of such Firm Order.\n(e) Title and risk of loss of the Safety Stock shall transfer to AMAG upon the delivery to AMAG of the Certificate of\nConformance (Device) and Certificate of Analyses (Device) for the applicable shipment of such Safety Stock from\nAntares\u2019 Subcontractor that manufactured such Safety Stock. Antares shall not be responsible for any insurance with\nrespect to the risk of loss of such Safety Stock.\n(f) In the event any Safety Stock expires, Antares or its Subcontractor shall dispose of or destroy such Safety Stock in\naccordance with the Quality Agreement. AMAG shall reimburse Antares for any costs or expenses incurred (without\nmarkup) in connection with such disposal or destruction.\n(g) Notwithstanding the quantities set forth in Section 3.6(a), Antares or its Subcontractor shall maintain and store the\nSafety Stock during the Term of this Agreement, provided that during the last [***] before expiration or termination\nof this Agreement, Antares or its Subcontractor is only required to maintain that amount of Safety Stock as is\nrequired to deliver amounts set forth in the then-current Forecast(s) until such expiration or termination date. AMAG\nshall reimburse Antares for any reasonable costs or expenses incurred (without markup) in connection with\nmaintaining or storing the Safety Stock.\n3.7 Manufacture at Risk.\n(a) In the event AMAG desires for Antares and/or its Subcontractor to initiate Manufacturing Services with respect to\nany Product or sample Product prior to the receipt of the Certificate of Analysis (PFS Manufacture) and the\nCertificate of Analysis (PFS ID Testing) (\u201cManufacture(d) at Risk\u201d), AMAG shall deliver written notice of such to\nAntares. Notwithstanding anything in this Agreement to the contrary, Antares shall not be required to perform any\nManufacturing Services with respect to the Product or sample Product until Antares receives (i) such written notice\nof AMAG\u2019s intention to Manufacture at Risk as set forth in the first sentence of this Section 3.7(a), or (ii) the\nCertificate of Analysis (PFS Manufacture) and the Certificate of Analysis (PFS ID Testing).\n(b) [***].\n- 17 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n(d) Antares or its Subcontractor shall manage the Safety Stock as part of its overall inventory and use the Safety Stock\nto fulfill its obligations pursuant to a Firm Orders on a first in/first out basis. As such inventory of Safety Stock is used\nas part of the Manufacturing Services of Product and/or sample Product, Antares shall use Commercially\nReasonable Efforts to replenish the Safety Stock to the level set forth in Section 3.6(a)(i) (as adjusted pursuant to\nSection 3.6(a)(ii)) within [***] of receipt of such Firm Order.\n(e) Title and risk of loss of the Safety Stock shall transfer to AMAG upon the delivery to AMAG of the Certificate of\nConformance (Device) and Certificate of Analyses (Device) for the applicable shipment of such Safety Stock from\nAntares\u2019 Subcontractor that manufactured such Safety Stock. Antares shall not be responsible for any insurance with\nrespect to the risk of loss of such Safety Stock.\n(f) In the event any Safety Stock expires, Antares or its Subcontractor shall dispose of or destroy such Safety Stock in\naccordance with the Quality Agreement. AMAG shall reimburse Antares for any costs or expenses incurred (without\nmarkup) in connection with such disposal or destruction.\n(g) Notwithstanding the quantities set forth in Section 3.6(a), Antares or its Subcontractor shall maintain and store the\nSafety Stock during the Term of this Agreement, provided that during the last [***] before expiration or termination\nof this Agreement, Antares or its Subcontractor is only required to maintain that amount of Safety Stock as is\nrequired to deliver amounts set forth in the then-current Forecast(s) until such expiration or termination date. AMAG\nshall reimburse Antares for any reasonable costs or expenses incurred (without markup) in connection with\nmaintaining or storing the Safety Stock.\n3.7 Manufacture at Risk.\n(a) In the event AMAG desires for Antares and/or its Subcontractor to initiate Manufacturing Services with respect to\nany Product or sample Product prior to the receipt of the Certificate of Analysis (PFS Manufacture) and the\nCertificate of Analysis (PFS ID Testing) (\u201cManufacture(d) at Risk\u201d), AMAG shall deliver written notice of such to\nAntares. Notwithstanding anything in this Agreement to the contrary, Antares shall not be required to perform any\nManufacturing Services with respect to the Product or sample Product until Antares receives (i) such written notice\nof AMAG\u2019s intention to Manufacture at Risk as set forth in the first sentence of this Section 3.7(a), or (ii) the\nCertificate of Analysis (PFS Manufacture) and the Certificate of Analysis (PFS ID Testing).\n(b) [***].\n- 17 -\n"}, "__type__": "4"}, "de8b5ea7-5f16-4a1c-8b3c-2187b50b46ad": {"__data__": {"id_": "de8b5ea7-5f16-4a1c-8b3c-2187b50b46ad", "embedding": null, "metadata": {"page_label": "19", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n3.8 Redundancy Plan. Antares shall, at the Party\u2019s respective costs set forth on Exhibit I, develop, implement and maintain an\nthe redundancy plan for molds, tooling and assemblies for the manufacturing of the Devices set forth on Exhibit I.\n3.9 Qualification of Second Source Supplier(s). Antares shall, upon AMAG\u2019s written request provided to Antares and at\nAMAG\u2019s cost (as set forth in this Section 3.9), identify and reasonably verify the suitability of one or more Third Persons\nas a \u201cbackup\u201d supplier of Devices (each, a \u201cSecond Source Supplier\u201d) in addition to Antares\u2019 then-current supplier of\nDevices (whether Antares or its then-current Subcontractor). Within [***] following the receipt of such written request,\nthe Parties will negotiate in good faith a budget for the costs and expenses associated with the Second Source Supplier,\nincluding all costs and expenses for the establishment and qualification thereof. Within [***] following the agreement by\nboth Parties of such budget, Antares will use Commercially Reasonable Efforts to establish and qualify such Second\nSource Supplier\u037e provided, however, that the Joint Project Team under the Development and License Agreement may\nagree to extend such time periods. AMAG shall have the right to propose a Second Source Supplier and Antares shall\nhave the right to consent to such Second Source Supplier, which consent shall not be unreasonably withheld or delayed.\nWithin [***] of a receipt of an invoice thereof, AMAG shall reimburse Antares for all documented costs and expenses\n(without markup) associated with the Second Source Supplier, including all documented costs and expense for the\nestablishment and qualification thereof\u037e provide that such costs and expenses, in the aggregate, shall not exceed [***] of\nthe agreed-upon budget (as set forth above).\n3.10 Right to Purchase Directly from Subcontractors or Second Source Suppliers.\n(a) If (i) a Force Majeure Event affecting solely Antares (specifically excluding its Subcontractors or Second Source\nSuppliers) lasts for [***] which prevents Antares from fulfilling its financial obligations to a Subcontractor or a\nSecond Source Supplier, or (ii) Antares is otherwise in material breach of its financial obligations to a Subcontractor\nor a Second Source Supplier for a period of at least [***] then Antares shall promptly deliver to AMAG a written\nnotice of such event or breach. Following the receipt of such notice, or following Antares\u2019 material breach of its\nobligation to deliver such notice under this Section 3.10(a), AMAG may deliver written notice to Antares of its\nintention to exercise its rights under this Section 3.10.\n(b) For the period commencing on Antares\u2019 receipt of such notice from AMAG as set forth in Section 3.10(a) and\nending [***] thereafter, Antares and AMAG shall negotiate in good faith a commercially reasonable agreement with\nrespect to the Force Majeure Event or material breach describe in Section 3.10(a)(i) or 3.10(a)(ii), respectively,\nwhich may include, AMAG advancing payment for Manufacturing Services on terms to be negotiated among the\nParties (an \u201cAlternate Arrangement\u201d). If, following the expiration of such [***] period, the Parties cannot mutually\nagree on a commercially\n- 18 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n3.8 Redundancy Plan. Antares shall, at the Party\u2019s respective costs set forth on Exhibit I, develop, implement and maintain an\nthe redundancy plan for molds, tooling and assemblies for the manufacturing of the Devices set forth on Exhibit I.\n3.9 Qualification of Second Source Supplier(s). Antares shall, upon AMAG\u2019s written request provided to Antares and at\nAMAG\u2019s cost (as set forth in this Section 3.9), identify and reasonably verify the suitability of one or more Third Persons\nas a \u201cbackup\u201d supplier of Devices (each, a \u201cSecond Source Supplier\u201d) in addition to Antares\u2019 then-current supplier of\nDevices (whether Antares or its then-current Subcontractor). Within [***] following the receipt of such written request,\nthe Parties will negotiate in good faith a budget for the costs and expenses associated with the Second Source Supplier,\nincluding all costs and expenses for the establishment and qualification thereof. Within [***] following the agreement by\nboth Parties of such budget, Antares will use Commercially Reasonable Efforts to establish and qualify such Second\nSource Supplier\u037e provided, however, that the Joint Project Team under the Development and License Agreement may\nagree to extend such time periods. AMAG shall have the right to propose a Second Source Supplier and Antares shall\nhave the right to consent to such Second Source Supplier, which consent shall not be unreasonably withheld or delayed.\nWithin [***] of a receipt of an invoice thereof, AMAG shall reimburse Antares for all documented costs and expenses\n(without markup) associated with the Second Source Supplier, including all documented costs and expense for the\nestablishment and qualification thereof\u037e provide that such costs and expenses, in the aggregate, shall not exceed [***] of\nthe agreed-upon budget (as set forth above).\n3.10 Right to Purchase Directly from Subcontractors or Second Source Suppliers.\n(a) If (i) a Force Majeure Event affecting solely Antares (specifically excluding its Subcontractors or Second Source\nSuppliers) lasts for [***] which prevents Antares from fulfilling its financial obligations to a Subcontractor or a\nSecond Source Supplier, or (ii) Antares is otherwise in material breach of its financial obligations to a Subcontractor\nor a Second Source Supplier for a period of at least [***] then Antares shall promptly deliver to AMAG a written\nnotice of such event or breach. Following the receipt of such notice, or following Antares\u2019 material breach of its\nobligation to deliver such notice under this Section 3.10(a), AMAG may deliver written notice to Antares of its\nintention to exercise its rights under this Section 3.10.\n(b) For the period commencing on Antares\u2019 receipt of such notice from AMAG as set forth in Section 3.10(a) and\nending [***] thereafter, Antares and AMAG shall negotiate in good faith a commercially reasonable agreement with\nrespect to the Force Majeure Event or material breach describe in Section 3.10(a)(i) or 3.10(a)(ii), respectively,\nwhich may include, AMAG advancing payment for Manufacturing Services on terms to be negotiated among the\nParties (an \u201cAlternate Arrangement\u201d). If, following the expiration of such [***] period, the Parties cannot mutually\nagree on a commercially\n- 18 -\n"}, "__type__": "4"}, "fabd1597-72ac-4dcf-9acc-d97cc9f6a2e7": {"__data__": {"id_": "fabd1597-72ac-4dcf-9acc-d97cc9f6a2e7", "embedding": null, "metadata": {"page_label": "20", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nreasonable agreement thereof, then, notwithstanding anything to the contrary in this Agreement, Antares shall use Commercially\nReasonable Efforts to enable AMAG to commence purchasing Devices, Components, Products, sample Products and/or Trainers\ndirectly from Antares\u2019 Subcontractors or Second Source Supplier(s) on substantially similar terms, including price, that Antares\nhas with such Subcontractor or Second Source Supplier(s) (as the case may be). AMAG\u2019s right to purchase Devices,\nComponents, Products, sample Products and/or Trainers directly from Antares\u2019 Subcontractor(s) or Second Source Supplier(s)\nshall continue to [***].\n(c) Provided that (i) AMAG and Antares have agreed to the terms of an Alternate Arrangement, or (ii) AMAG\ncommences purchasing Devices, Components, Products, sample Products and/or Trainers directly from Antares\u2019\nSubcontractors or Second Source Supplier(s) pursuant to the terms of Section 3.10(b), AMAG\u2019s election of its right\nto purchase Devices, Components, Products, sample Products and/or Trainers directly from Antares\u2019\nSubcontractor(s) or Second Source Supplier(s) under this Section 3.10 shall be AMAG\u2019s sole and exclusive\nremedy, and Antares\u2019 sole liability, with respect to Antares\u2019 failure to supply such Devices, Components, Products,\nsample Products and/or Trainers for the reasons specified in Section 3.10(a)\u037e provided, that, if AMAG does not\nelect such right, AMAG shall not be prohibited from exercising all other rights available to AMAG under this\nAgreement and at law.\nARTICLE 4 \nPRICE AND PAYMENT\n4.1 Prices.\n(a) During the Term, Antares or its Subcontractor shall deliver Products, sample Products and Trainers ordered by\nAMAG in accordance with this Agreement at the Transfer Prices set forth on Exhibit D.\n(b) [***].\n4.2 Invoices and Payment.\n[***].\n4.3Records\u037e Financial Audit Request. With respect to audits of Antares\u2019 records relating to the establishment of the Transfer Price,\n[***] or any other amounts payable by AMAG hereunder, including, without limitation, pursuant to Section 4.6, Article 11 of\nthe Development and License Agreement is hereby incorporated by reference herein and made a part of this Agreement.\n4.4Taxes.\n- 19 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nreasonable agreement thereof, then, notwithstanding anything to the contrary in this Agreement, Antares shall use Commercially\nReasonable Efforts to enable AMAG to commence purchasing Devices, Components, Products, sample Products and/or Trainers\ndirectly from Antares\u2019 Subcontractors or Second Source Supplier(s) on substantially similar terms, including price, that Antares\nhas with such Subcontractor or Second Source Supplier(s) (as the case may be). AMAG\u2019s right to purchase Devices,\nComponents, Products, sample Products and/or Trainers directly from Antares\u2019 Subcontractor(s) or Second Source Supplier(s)\nshall continue to [***].\n(c) Provided that (i) AMAG and Antares have agreed to the terms of an Alternate Arrangement, or (ii) AMAG\ncommences purchasing Devices, Components, Products, sample Products and/or Trainers directly from Antares\u2019\nSubcontractors or Second Source Supplier(s) pursuant to the terms of Section 3.10(b), AMAG\u2019s election of its right\nto purchase Devices, Components, Products, sample Products and/or Trainers directly from Antares\u2019\nSubcontractor(s) or Second Source Supplier(s) under this Section 3.10 shall be AMAG\u2019s sole and exclusive\nremedy, and Antares\u2019 sole liability, with respect to Antares\u2019 failure to supply such Devices, Components, Products,\nsample Products and/or Trainers for the reasons specified in Section 3.10(a)\u037e provided, that, if AMAG does not\nelect such right, AMAG shall not be prohibited from exercising all other rights available to AMAG under this\nAgreement and at law.\nARTICLE 4 \nPRICE AND PAYMENT\n4.1 Prices.\n(a) During the Term, Antares or its Subcontractor shall deliver Products, sample Products and Trainers ordered by\nAMAG in accordance with this Agreement at the Transfer Prices set forth on Exhibit D.\n(b) [***].\n4.2 Invoices and Payment.\n[***].\n4.3Records\u037e Financial Audit Request. With respect to audits of Antares\u2019 records relating to the establishment of the Transfer Price,\n[***] or any other amounts payable by AMAG hereunder, including, without limitation, pursuant to Section 4.6, Article 11 of\nthe Development and License Agreement is hereby incorporated by reference herein and made a part of this Agreement.\n4.4Taxes.\n- 19 -\n"}, "__type__": "4"}, "7be6d76d-4153-4b2a-8195-dce079e20453": {"__data__": {"id_": "7be6d76d-4153-4b2a-8195-dce079e20453", "embedding": null, "metadata": {"page_label": "21", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n(a) The Transfer Price includes all taxes except (i) such sales and use taxes which Antares is required by law to collect\nfrom AMAG and (ii) to the extent imposed on the date of this Agreement or as a result of a change in law, VAT.\nSuch VAT and taxes, if any, will be payable in addition to the Transfer Price. Where Antares is required by law to\ncollect and/or account for such VAT and taxes from AMAG, such VAT and taxes will be separately stated in\nAntares\u2019s Invoice and will be paid by AMAG to Antares unless AMAG provides an exemption to Antares and, in\nthe case of VAT, subject to Antares providing a valid VAT invoice to AMAG in the form and manner required by law\nto allow AMAG to recover such VAT (to the extent AMAG is allowed to do so by law). For avoidance of doubt,\nany increase in VAT imposed as a result of any action taken by Antares, and not consented to by AMAG, after the\ndate of this Agreement shall not be paid by AMAG or otherwise included in the Transfer Price.\n(b) Except where AMAG is required by Applicable Law to account for any VAT to the applicable Governmental\nAuthority, Antares shall be solely responsible for the timely payment of all such VAT and taxes to the applicable\nGovernmental Authority\n(c) Notwithstanding the foregoing in this Section 4.4, AMAG shall be responsible for the payment of all duties, tariffs,\nVAT, taxes and similar charges payable on the exportation or importation of the Products, sample Products or\nTrainers. Without limiting any of Antares\u2019s obligations hereunder, Antares shall cooperate with and assist AMAG in\nall aspects of the shipment, exportation, importation and delivery process in order to ensure the expeditious delivery\nof the Product to the designated delivery point, including assisting in obtaining any documents that may be required.\n4.5[***].\n4.6[***].\nARTICLE 5 \nPRODUCT CLAIMS AND RECALLS\n5.1 Product Claims.\n(a) Product Claims. [***].\n(b) Determination of Deficiency. [***].\n(c) Shortages. [***].\n5.2 Product Recalls and Returns.\n- 20 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n(a) The Transfer Price includes all taxes except (i) such sales and use taxes which Antares is required by law to collect\nfrom AMAG and (ii) to the extent imposed on the date of this Agreement or as a result of a change in law, VAT.\nSuch VAT and taxes, if any, will be payable in addition to the Transfer Price. Where Antares is required by law to\ncollect and/or account for such VAT and taxes from AMAG, such VAT and taxes will be separately stated in\nAntares\u2019s Invoice and will be paid by AMAG to Antares unless AMAG provides an exemption to Antares and, in\nthe case of VAT, subject to Antares providing a valid VAT invoice to AMAG in the form and manner required by law\nto allow AMAG to recover such VAT (to the extent AMAG is allowed to do so by law). For avoidance of doubt,\nany increase in VAT imposed as a result of any action taken by Antares, and not consented to by AMAG, after the\ndate of this Agreement shall not be paid by AMAG or otherwise included in the Transfer Price.\n(b) Except where AMAG is required by Applicable Law to account for any VAT to the applicable Governmental\nAuthority, Antares shall be solely responsible for the timely payment of all such VAT and taxes to the applicable\nGovernmental Authority\n(c) Notwithstanding the foregoing in this Section 4.4, AMAG shall be responsible for the payment of all duties, tariffs,\nVAT, taxes and similar charges payable on the exportation or importation of the Products, sample Products or\nTrainers. Without limiting any of Antares\u2019s obligations hereunder, Antares shall cooperate with and assist AMAG in\nall aspects of the shipment, exportation, importation and delivery process in order to ensure the expeditious delivery\nof the Product to the designated delivery point, including assisting in obtaining any documents that may be required.\n4.5[***].\n4.6[***].\nARTICLE 5 \nPRODUCT CLAIMS AND RECALLS\n5.1 Product Claims.\n(a) Product Claims. [***].\n(b) Determination of Deficiency. [***].\n(c) Shortages. [***].\n5.2 Product Recalls and Returns.\n- 20 -\n"}, "__type__": "4"}, "92065c78-1e41-4794-b2b8-1a97e26684fe": {"__data__": {"id_": "92065c78-1e41-4794-b2b8-1a97e26684fe", "embedding": null, "metadata": {"page_label": "22", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n(a) Records and Notice. In addition to the requirements of Section 6.2, Antares and AMAG shall each maintain such\nrecords in compliance with Applicable Laws as is reasonably necessary to permit a Recall of any Products, sample\nProducts and Trainers delivered to AMAG, AMAG\u2019s designee or customers of AMAG. Each Party shall promptly\n(but no later than [***] of receipt of such information) notify the other by telephone (to be confirmed in writing) of\nany information which might affect the marketability, safety, or effectiveness of the Products, sample Products or\nTrainers and/or which might result in the Recall or seizure of the Products, sample Products, or Trainers. Upon\nreceiving any such notice or upon any such discovery, each Party shall cease and desist from further shipments of\nsuch Products, sample Products or Trainers in its possession or control until a decision by AMAG has been made\nwhether a Recall or some other corrective action is necessary.\n(b) Recalls. The decision to initiate a Recall or to take some other corrective action, if any, shall be made and\nimplemented by AMAG in its sole discretion after consultation with Antares. AMAG shall be responsible for\nmanaging all Recalls and Antares shall cooperate with AMAG as AMAG may reasonably request. Subject to\nAntares\u2019 obligation to cover the costs set forth in Section 5.3(b), AMAG shall be responsible for all costs incurred\ndue to the Recall of a Product, sample Product or Trainer.\n(c) Product Returns. AMAG shall have the responsibility for handling customer returns of the Products, sample\nProducts and Trainers.\n5.3 Antares\u2019 Responsibility for Defective and Recalled Products.\n(a) Defective Product. [***].\n(b) Recalled Product. [***].\n5.4 Disposition of Defective or Recalled Products . AMAG shall not dispose of any damaged, defective, returned or\nRecalled Products, sample Products or Trainers in relation to which it intends to assert a claim against Antares without\nAntares\u2019 prior written authorization to do so, unless otherwise required by Applicable Laws. Alternatively, Antares may\ninstruct AMAG to return such Products, sample Products and Trainers to Antares at Antares\u2019 expense. Antares shall bear\nthe cost of disposition with respect to any damaged, defective, returned or Recalled Products, sample Products or Trainers\nin relation to which it bears responsibility under Sections 5.1, 5.2 or 5.3 hereof. In all other circumstances, AMAG shall\nbear the cost of disposition with respect to any damaged, defective, returned or Recalled Products, sample Products and\nTrainers.\n5.5 Customer Questions or Complaints. AMAG shall have the sole right and responsibility for responding to questions and\ncomplaints from AMAG\u2019s customers. Antares shall refer any questions and complaints (including safety and efficacy\ninquiries, quality complaints\n- 21 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n(a) Records and Notice. In addition to the requirements of Section 6.2, Antares and AMAG shall each maintain such\nrecords in compliance with Applicable Laws as is reasonably necessary to permit a Recall of any Products, sample\nProducts and Trainers delivered to AMAG, AMAG\u2019s designee or customers of AMAG. Each Party shall promptly\n(but no later than [***] of receipt of such information) notify the other by telephone (to be confirmed in writing) of\nany information which might affect the marketability, safety, or effectiveness of the Products, sample Products or\nTrainers and/or which might result in the Recall or seizure of the Products, sample Products, or Trainers. Upon\nreceiving any such notice or upon any such discovery, each Party shall cease and desist from further shipments of\nsuch Products, sample Products or Trainers in its possession or control until a decision by AMAG has been made\nwhether a Recall or some other corrective action is necessary.\n(b) Recalls. The decision to initiate a Recall or to take some other corrective action, if any, shall be made and\nimplemented by AMAG in its sole discretion after consultation with Antares. AMAG shall be responsible for\nmanaging all Recalls and Antares shall cooperate with AMAG as AMAG may reasonably request. Subject to\nAntares\u2019 obligation to cover the costs set forth in Section 5.3(b), AMAG shall be responsible for all costs incurred\ndue to the Recall of a Product, sample Product or Trainer.\n(c) Product Returns. AMAG shall have the responsibility for handling customer returns of the Products, sample\nProducts and Trainers.\n5.3 Antares\u2019 Responsibility for Defective and Recalled Products.\n(a) Defective Product. [***].\n(b) Recalled Product. [***].\n5.4 Disposition of Defective or Recalled Products . AMAG shall not dispose of any damaged, defective, returned or\nRecalled Products, sample Products or Trainers in relation to which it intends to assert a claim against Antares without\nAntares\u2019 prior written authorization to do so, unless otherwise required by Applicable Laws. Alternatively, Antares may\ninstruct AMAG to return such Products, sample Products and Trainers to Antares at Antares\u2019 expense. Antares shall bear\nthe cost of disposition with respect to any damaged, defective, returned or Recalled Products, sample Products or Trainers\nin relation to which it bears responsibility under Sections 5.1, 5.2 or 5.3 hereof. In all other circumstances, AMAG shall\nbear the cost of disposition with respect to any damaged, defective, returned or Recalled Products, sample Products and\nTrainers.\n5.5 Customer Questions or Complaints. AMAG shall have the sole right and responsibility for responding to questions and\ncomplaints from AMAG\u2019s customers. Antares shall refer any questions and complaints (including safety and efficacy\ninquiries, quality complaints\n- 21 -\n"}, "__type__": "4"}, "a1f5fe48-be6e-466b-9c51-d1192e12fcf5": {"__data__": {"id_": "a1f5fe48-be6e-466b-9c51-d1192e12fcf5", "embedding": null, "metadata": {"page_label": "23", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nand adverse event reports) that it receives concerning the Device or the Products, sample Products or Trainers to AMAG\n(together with all available evidence and other information relating thereto) as soon as practicable and, in any event within [***] of\nAntares\u2019 receipt of such question or complaint\u037e provided that all complaints concerning Product and sample Product tampering,\ncontamination or mix-up (e.g., wrong ingredients) shall be delivered within [***] of Antares\u2019 receipt thereof. Antares shall not take\nany further action in connection with any such questions or complaints without the consent of AMAG, but shall cooperate in the\ninvestigation and closure of any such questions or complaints at the request of AMAG. Such assistance shall include follow-up\ninvestigations, including testing. In addition, Antares shall provide AMAG with all information to enable AMAG to respond\nproperly to questions or complaints relating to the Products and sample Products as provided in the Quality Agreement.\nARTICLE 6 \nCO-OPERATION\u037e QUALITY AUDIT\u037e REGULATORY FILINGS\n6.1 Governmental Agencies. Subject to the Regulatory Authority inspection obligations set forth in Section 6.3, Antares\nand/or its Subcontractor(s) may communicate with any Regulatory Authority regarding the Products, sample Products and\nTrainers only if, in the reasonable opinion of Antares\u2019 and/or its Subcontractor\u2019s counsel, such communication is necessary\nto comply with the terms of this Agreement or Applicable Laws\u037e provided, however, that unless, in the reasonable opinion\nof Antares\u2019 and/or its Subcontractor\u2019s counsel, there is a legal prohibition against doing so, Antares shall notify AMAG\nreasonably in advance of any such communication and permit AMAG to accompany Antares and/or its Subcontractor and\ntake part in any communications with such Regulatory Authority, and provide AMAG with copies of all such\ncommunications from such Regulatory Authority.\n6.2 Records and Accounting by Antares . Antares shall keep records of the manufacture, testing and shipping of the\nProducts, sample Products and Trainers and retain samples of such Products, sample Products and Trainers as are\nnecessary to comply with cGMPs, Applicable Laws, the Quality Agreement, and manufacturing regulatory requirements\napplicable to Antares, as well as to assist with resolving Product, sample Product and Trainer complaints and other similar\ninvestigations. Copies of such records and samples shall be retained for the respective periods set forth in the Quality\nAgreement.\n6.3 Regulatory Inspections. Antares shall permit the FDA and other Regulatory Authorities to conduct inspections of each\nManufacturing Site as they may request, including pre-approval inspections, and shall cooperate with such Regulatory\nAuthorities with respect to the inspections and any related matters, in each case which is related to the Device, Product or\nsample Product. Antares shall give AMAG notice within [***] of becoming aware of any such inspections, and keep\nAMAG reasonably informed about the results and conclusions of each regulatory inspection, including actions taken by\nAntares or its Subcontractor to\n- 22 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nand adverse event reports) that it receives concerning the Device or the Products, sample Products or Trainers to AMAG\n(together with all available evidence and other information relating thereto) as soon as practicable and, in any event within [***] of\nAntares\u2019 receipt of such question or complaint\u037e provided that all complaints concerning Product and sample Product tampering,\ncontamination or mix-up (e.g., wrong ingredients) shall be delivered within [***] of Antares\u2019 receipt thereof. Antares shall not take\nany further action in connection with any such questions or complaints without the consent of AMAG, but shall cooperate in the\ninvestigation and closure of any such questions or complaints at the request of AMAG. Such assistance shall include follow-up\ninvestigations, including testing. In addition, Antares shall provide AMAG with all information to enable AMAG to respond\nproperly to questions or complaints relating to the Products and sample Products as provided in the Quality Agreement.\nARTICLE 6 \nCO-OPERATION\u037e QUALITY AUDIT\u037e REGULATORY FILINGS\n6.1 Governmental Agencies. Subject to the Regulatory Authority inspection obligations set forth in Section 6.3, Antares\nand/or its Subcontractor(s) may communicate with any Regulatory Authority regarding the Products, sample Products and\nTrainers only if, in the reasonable opinion of Antares\u2019 and/or its Subcontractor\u2019s counsel, such communication is necessary\nto comply with the terms of this Agreement or Applicable Laws\u037e provided, however, that unless, in the reasonable opinion\nof Antares\u2019 and/or its Subcontractor\u2019s counsel, there is a legal prohibition against doing so, Antares shall notify AMAG\nreasonably in advance of any such communication and permit AMAG to accompany Antares and/or its Subcontractor and\ntake part in any communications with such Regulatory Authority, and provide AMAG with copies of all such\ncommunications from such Regulatory Authority.\n6.2 Records and Accounting by Antares . Antares shall keep records of the manufacture, testing and shipping of the\nProducts, sample Products and Trainers and retain samples of such Products, sample Products and Trainers as are\nnecessary to comply with cGMPs, Applicable Laws, the Quality Agreement, and manufacturing regulatory requirements\napplicable to Antares, as well as to assist with resolving Product, sample Product and Trainer complaints and other similar\ninvestigations. Copies of such records and samples shall be retained for the respective periods set forth in the Quality\nAgreement.\n6.3 Regulatory Inspections. Antares shall permit the FDA and other Regulatory Authorities to conduct inspections of each\nManufacturing Site as they may request, including pre-approval inspections, and shall cooperate with such Regulatory\nAuthorities with respect to the inspections and any related matters, in each case which is related to the Device, Product or\nsample Product. Antares shall give AMAG notice within [***] of becoming aware of any such inspections, and keep\nAMAG reasonably informed about the results and conclusions of each regulatory inspection, including actions taken by\nAntares or its Subcontractor to\n- 22 -\n"}, "__type__": "4"}, "80fcf24d-2508-4ee0-8d82-763f5aa4db2c": {"__data__": {"id_": "80fcf24d-2508-4ee0-8d82-763f5aa4db2c", "embedding": null, "metadata": {"page_label": "24", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nremedy conditions cited in the inspections, to the extent such results and conclusions relate to the Device, Product or sample\nProduct. In addition, Antares will promptly provide AMAG with copies of any written inspection reports issued by Regulatory\nAuthorities and all correspondence between Antares and Regulatory Authorities, including, but not limited to, FDA Form 483,\nNotice of Observation, and all related correspondence, in each case only to the extent relating to the Device, Product or sample\nProduct or general manufacturing concerns related to the Device, Product or sample Product, which in all cases may be\nreasonably redacted by Antares to protect confidential information of Antares or its partners, licensees or licensors. Antares\nagrees to promptly notify and provide AMAG copies of any request, directive or other communication of the FDA or other\nRegulatory Authority relating to the Device, Product or sample Product and to reasonably cooperate with AMAG in responding\nto such requests, directives and communications.\n6.4 Quality Audit. The Parties rights and obligations with respect to quality assurance audits are set forth in the Quality\nAgreement.\n6.5 Reports. Antares will promptly supply on an annual basis and when reasonably requested by AMAG from time to time, at\nno additional charge, all available information and data in its control that AMAG reasonably requires in order to complete\nany filing for, or apply for, obtain or maintain, regulatory approvals under any applicable regulatory regime (including any\nAnnual Report that AMAG is required to file with the FDA), including without limitation information relating to the\nManufacturing Site, Development Report (as described in ICH guidelines), Manufacturing Services, Device, Product,\nsample Product, Trainers or the process, methodology, raw materials and intermediates used in the manufacture,\nprocessing, or packaging of the Device, Product, sample Product or Trainers, release test results, complaint test results, all\ninvestigations (in manufacturing, testing and storage), and all information required to be submitted in the CMC (chemistry,\nmanufacturing and controls) section of an IND or a NDA or other regulatory filings, or required or requested to be\nprovided to any Regulatory Authority. At AMAG\u2019s reasonable written request, Antares shall be responsible for supporting\nAMAG\u2019s Annual Product Review Report, consistent with cGMPs, Applicable Laws, and customary FDA or other\nRegulatory Authority requirements. Any additional report requested by AMAG beyond the scope of what is required or\nrecommended under cGMPs, Applicable Laws and customary FDA or other Regulatory Authority requirements shall be\nsubject to an additional fee to be agreed upon between Antares and AMAG. In addition, Antares shall cooperate with\nAMAG with respect to all reporting obligations relevant to the Product, sample Product and Trainers under Applicable\nLaws.\n6.6 Regulatory Filings. Responsibility for regulatory filings shall be as set forth in Section 4.1 of the Development and\nLicense Agreement.\n- 23 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nremedy conditions cited in the inspections, to the extent such results and conclusions relate to the Device, Product or sample\nProduct. In addition, Antares will promptly provide AMAG with copies of any written inspection reports issued by Regulatory\nAuthorities and all correspondence between Antares and Regulatory Authorities, including, but not limited to, FDA Form 483,\nNotice of Observation, and all related correspondence, in each case only to the extent relating to the Device, Product or sample\nProduct or general manufacturing concerns related to the Device, Product or sample Product, which in all cases may be\nreasonably redacted by Antares to protect confidential information of Antares or its partners, licensees or licensors. Antares\nagrees to promptly notify and provide AMAG copies of any request, directive or other communication of the FDA or other\nRegulatory Authority relating to the Device, Product or sample Product and to reasonably cooperate with AMAG in responding\nto such requests, directives and communications.\n6.4 Quality Audit. The Parties rights and obligations with respect to quality assurance audits are set forth in the Quality\nAgreement.\n6.5 Reports. Antares will promptly supply on an annual basis and when reasonably requested by AMAG from time to time, at\nno additional charge, all available information and data in its control that AMAG reasonably requires in order to complete\nany filing for, or apply for, obtain or maintain, regulatory approvals under any applicable regulatory regime (including any\nAnnual Report that AMAG is required to file with the FDA), including without limitation information relating to the\nManufacturing Site, Development Report (as described in ICH guidelines), Manufacturing Services, Device, Product,\nsample Product, Trainers or the process, methodology, raw materials and intermediates used in the manufacture,\nprocessing, or packaging of the Device, Product, sample Product or Trainers, release test results, complaint test results, all\ninvestigations (in manufacturing, testing and storage), and all information required to be submitted in the CMC (chemistry,\nmanufacturing and controls) section of an IND or a NDA or other regulatory filings, or required or requested to be\nprovided to any Regulatory Authority. At AMAG\u2019s reasonable written request, Antares shall be responsible for supporting\nAMAG\u2019s Annual Product Review Report, consistent with cGMPs, Applicable Laws, and customary FDA or other\nRegulatory Authority requirements. Any additional report requested by AMAG beyond the scope of what is required or\nrecommended under cGMPs, Applicable Laws and customary FDA or other Regulatory Authority requirements shall be\nsubject to an additional fee to be agreed upon between Antares and AMAG. In addition, Antares shall cooperate with\nAMAG with respect to all reporting obligations relevant to the Product, sample Product and Trainers under Applicable\nLaws.\n6.6 Regulatory Filings. Responsibility for regulatory filings shall be as set forth in Section 4.1 of the Development and\nLicense Agreement.\n- 23 -\n"}, "__type__": "4"}, "07a25142-cc33-43f8-a952-994c8f584fc2": {"__data__": {"id_": "07a25142-cc33-43f8-a952-994c8f584fc2", "embedding": null, "metadata": {"page_label": "25", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nARTICLE 7 \nTERM AND TERMINATION\n7.1 Term. Subject to early termination of this Agreement pursuant to Sections 7.2, 7.3 or 7.4, this Agreement shall become\neffective as of the Effective Date and shall continue until the expiration or earlier termination of the Development and\nLicense Agreement (the \u201cTerm\u201d).\n7.2 Termination By AMAG. This Agreement may be terminated in its entirety by AMAG, upon AMAG\u2019s prior written\nnotice to Antares:\n(a) Subject to Sections 11.1 and 12.4, if Antares commits a material breach of this Agreement and such material breach\nremains uncured for [***] following written notice of breach by Antares. Notwithstanding the foregoing, AMAG\u2019s\ntermination rights with respect to an Antares\u2019 failure to supply Products, sample Products or Trainers, including a\nSupply Failure, are not subject this Section 7.2(a) and are set forth in Section 7.2(b)\u037e\n(b) Subject to Section 12.4, if a Supply Failure remains uncured for [***] following written notice of such failure to\nAntares\u037e provided, however, that AMAG may not terminate this Agreement if Antares\u2019 failure to supply Products,\nsample Products or Trainers is a result of Force Majeure Event under Section 12.4 or AMAG\u2019s breach of this\nAgreement including, but not limited to, failure to provide adequate quantities of Prefilled Syringe\u037e\n(c) If Antares is subject to a petition for relief under any bankruptcy legislation, or makes an assignment for the benefit of\ncreditors, or is subject to the appointment of a receiver for all or a substantial part of Antares\u2019 assets, and such\npetition, assignment or appointment prevents Antares (as a legal or as a practical matter) from performing its\nobligations under this Agreement, or such petition, assignment or appointment is not otherwise dismissed or vacated\nwithin [***]\u037e or\n(d) Upon [***] written notice to Antares in the event that AMAG permanently ceases commercializing the Product for\nefficacy or safety reasons, as evidenced by the placement of the Product on the Discontinued Drug Product List of\nthe FDA Orange Book publication (\u201cApproved Drug Products with Therapeutic Equivalence Evaluations\u201d).\n7.3 Termination by Antares. This Agreement may be terminated in its entirety by Antares upon Antares\u2019 prior written notice\nto AMAG:\n(a) Subject to Sections 11.1 and 12.4, if AMAG commits a material breach of this Agreement and such material breach\nremains uncured for [***] following written notice of breach by Antares\u037e\n- 24 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nARTICLE 7 \nTERM AND TERMINATION\n7.1 Term. Subject to early termination of this Agreement pursuant to Sections 7.2, 7.3 or 7.4, this Agreement shall become\neffective as of the Effective Date and shall continue until the expiration or earlier termination of the Development and\nLicense Agreement (the \u201cTerm\u201d).\n7.2 Termination By AMAG. This Agreement may be terminated in its entirety by AMAG, upon AMAG\u2019s prior written\nnotice to Antares:\n(a) Subject to Sections 11.1 and 12.4, if Antares commits a material breach of this Agreement and such material breach\nremains uncured for [***] following written notice of breach by Antares. Notwithstanding the foregoing, AMAG\u2019s\ntermination rights with respect to an Antares\u2019 failure to supply Products, sample Products or Trainers, including a\nSupply Failure, are not subject this Section 7.2(a) and are set forth in Section 7.2(b)\u037e\n(b) Subject to Section 12.4, if a Supply Failure remains uncured for [***] following written notice of such failure to\nAntares\u037e provided, however, that AMAG may not terminate this Agreement if Antares\u2019 failure to supply Products,\nsample Products or Trainers is a result of Force Majeure Event under Section 12.4 or AMAG\u2019s breach of this\nAgreement including, but not limited to, failure to provide adequate quantities of Prefilled Syringe\u037e\n(c) If Antares is subject to a petition for relief under any bankruptcy legislation, or makes an assignment for the benefit of\ncreditors, or is subject to the appointment of a receiver for all or a substantial part of Antares\u2019 assets, and such\npetition, assignment or appointment prevents Antares (as a legal or as a practical matter) from performing its\nobligations under this Agreement, or such petition, assignment or appointment is not otherwise dismissed or vacated\nwithin [***]\u037e or\n(d) Upon [***] written notice to Antares in the event that AMAG permanently ceases commercializing the Product for\nefficacy or safety reasons, as evidenced by the placement of the Product on the Discontinued Drug Product List of\nthe FDA Orange Book publication (\u201cApproved Drug Products with Therapeutic Equivalence Evaluations\u201d).\n7.3 Termination by Antares. This Agreement may be terminated in its entirety by Antares upon Antares\u2019 prior written notice\nto AMAG:\n(a) Subject to Sections 11.1 and 12.4, if AMAG commits a material breach of this Agreement and such material breach\nremains uncured for [***] following written notice of breach by Antares\u037e\n- 24 -\n"}, "__type__": "4"}, "a94ad7fe-4e06-4ced-9b0b-0919bc313f64": {"__data__": {"id_": "a94ad7fe-4e06-4ced-9b0b-0919bc313f64", "embedding": null, "metadata": {"page_label": "26", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n(b) If AMAG is subject to a petition for relief under any bankruptcy legislation, or makes an assignment for the benefit of\ncreditors, or is subject to the appointment of a receiver for all or a substantial part of AMAG\u2019s assets, and such\npetition, assignment or appointment prevents AMAG (as a legal or as a practical matter) from performing its\nobligations under this Agreement, or such petition, assignment or appointment is not otherwise dismissed or vacated\nwithin [***]\u037e or\n(c) Upon [***] written notice to AMAG in the event that AMAG permanently ceases commercializing the Product for\nefficacy or safety reasons, as evidenced by the placement of the Product on the Discontinued Drug Product List of\nthe FDA Orange Book publication (\u201cApproved Drug Products with Therapeutic Equivalence Evaluations\u201d).\n7.4 Co-Termination. Without further action by either Party, this Agreement shall automatically terminate effective immediately\nupon the termination of the Development and License Agreement in its entirety, subject to the provisions that expressly\nsurvive the termination thereof.\n7.5 Remedies for Material Breach.\n(a) Remedies for AMAG. Subject to Sections 11.1 and 12.4, in the event of an uncured material breach by Antares that\nwould entitle AMAG to terminate this Agreement under Section 7.2(a) and Section 7.2(b), in addition to and\nindependent of AMAG\u2019s right to terminate this Agreement, AMAG may seek monetary damages (whether or not\nthis Agreement is terminated) for such material breach and/or equitable relief to prevent such material breach from\ncontinuing or occurring again in the future.\n(b) Remedies for Antares. Subject to Sections 11.1 and 12.4, in the event of a uncured material breach by AMAG that\nwould entitle Antares to terminate this Agreement under Section 7.3(a), in addition to and independent of Antares\u2019\nright to terminate this Agreement, Antares may seek monetary damages (whether or not this Agreement is\nterminated) for such material breach and/or equitable relief to prevent such material breach from continuing or\noccurring again in the future.\n7.6 Effects of Expiration or Termination of this Agreement.\n(a) If this Agreement expires or is terminated for any reason, then (in addition to any other remedies either Party may\nhave in the event of material breach by the other Party):\n[***].\n(b) [***].\n(c) [***].\n- 25 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n(b) If AMAG is subject to a petition for relief under any bankruptcy legislation, or makes an assignment for the benefit of\ncreditors, or is subject to the appointment of a receiver for all or a substantial part of AMAG\u2019s assets, and such\npetition, assignment or appointment prevents AMAG (as a legal or as a practical matter) from performing its\nobligations under this Agreement, or such petition, assignment or appointment is not otherwise dismissed or vacated\nwithin [***]\u037e or\n(c) Upon [***] written notice to AMAG in the event that AMAG permanently ceases commercializing the Product for\nefficacy or safety reasons, as evidenced by the placement of the Product on the Discontinued Drug Product List of\nthe FDA Orange Book publication (\u201cApproved Drug Products with Therapeutic Equivalence Evaluations\u201d).\n7.4 Co-Termination. Without further action by either Party, this Agreement shall automatically terminate effective immediately\nupon the termination of the Development and License Agreement in its entirety, subject to the provisions that expressly\nsurvive the termination thereof.\n7.5 Remedies for Material Breach.\n(a) Remedies for AMAG. Subject to Sections 11.1 and 12.4, in the event of an uncured material breach by Antares that\nwould entitle AMAG to terminate this Agreement under Section 7.2(a) and Section 7.2(b), in addition to and\nindependent of AMAG\u2019s right to terminate this Agreement, AMAG may seek monetary damages (whether or not\nthis Agreement is terminated) for such material breach and/or equitable relief to prevent such material breach from\ncontinuing or occurring again in the future.\n(b) Remedies for Antares. Subject to Sections 11.1 and 12.4, in the event of a uncured material breach by AMAG that\nwould entitle Antares to terminate this Agreement under Section 7.3(a), in addition to and independent of Antares\u2019\nright to terminate this Agreement, Antares may seek monetary damages (whether or not this Agreement is\nterminated) for such material breach and/or equitable relief to prevent such material breach from continuing or\noccurring again in the future.\n7.6 Effects of Expiration or Termination of this Agreement.\n(a) If this Agreement expires or is terminated for any reason, then (in addition to any other remedies either Party may\nhave in the event of material breach by the other Party):\n[***].\n(b) [***].\n(c) [***].\n- 25 -\n"}, "__type__": "4"}, "1a1c442d-8b85-4512-adca-0d80e14d0a40": {"__data__": {"id_": "1a1c442d-8b85-4512-adca-0d80e14d0a40", "embedding": null, "metadata": {"page_label": "27", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n(d) [***].\n(e) Except with respect to AMAG\u2019s right to sell off existing inventory as set forth in Section 7.6(d), the Parties\nacknowledge and agree that following any expiration or termination of this Agreement, all rights and licenses granted\nto AMAG under this Agreement or the Development and License Agreement shall terminate and AMAG shall cease\nusing and selling any Products, sample Products or Trainers.\n(f) Any termination or expiration of this Agreement shall not affect any outstanding obligations or payments due\nhereunder prior to such termination or expiration, nor shall it prejudice any other remedies that the Parties may have\nunder this Agreement or Applicable Laws (except as otherwise provided in this Agreement). For greater certainty,\ntermination of this Agreement for any reason shall not affect the obligations and responsibilities of the Parties\npursuant to ARTICLE 1 (Interpretation), ARTICLE 9 (Remedies and Indemnities) (provided that, the obligation to\nmaintain the insurance coverages set forth in Section 9.3 shall only survive for the time period set forth therein),\nARTICLE 10 (Confidentiality), ARTICLE 11 (Dispute Resolution), and Sections 2.9 (Retained Samples) (for the\nperiod set forth therein), 4.4 (Taxes), 5.2 (Product Recalls and Returns)\u037e 5.5 (Customer Questions or Complaints)\n(for a period of [***] from the date of termination or expiration)\u037e 6.2 (Regulatory and Accounting by Antares) (for\nthe period set forth therein), 7.6 (Effects of Expiration or Termination of this Agreement), 12.1 (Agency), 12.2\n(Assignment) 12.5 (Notices), 12.6 (Amendment), 12.7 (Waiver) and 12.10 (Governing Law), all of which survive\nany termination or expiration.\n(g) Termination, relinquishment or expiration of the Agreement for any reason shall be without prejudice to any rights\nwhich shall have accrued to the benefit of either Party prior to (or as a result of, including, without limitation, rights\navailable under law and equity) such termination, relinquishment or expiration. Such termination, relinquishment or\nexpiration shall not relieve either Party from obligations that are expressly indicated to survive termination or\nexpiration of the Agreement.\n7.7 [***].\nARTICLE 8 \nREPRESENTATIONS, WARRANTIES AND COVENANTS\n8.1 Authority. Each Party hereby represents, warrants and covenants to the other Party that: (i) it has the full right and authority\nto enter into this Agreement and to grant to the other Party the rights granted to such other Party under this Agreement, (ii)\nit has obtained all necessary corporate approvals to enter and execute this Agreement, and (iii) that it is not aware of any\nimpediment that would inhibit its ability to perform its obligations hereunder.\n- 26 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n(d) [***].\n(e) Except with respect to AMAG\u2019s right to sell off existing inventory as set forth in Section 7.6(d), the Parties\nacknowledge and agree that following any expiration or termination of this Agreement, all rights and licenses granted\nto AMAG under this Agreement or the Development and License Agreement shall terminate and AMAG shall cease\nusing and selling any Products, sample Products or Trainers.\n(f) Any termination or expiration of this Agreement shall not affect any outstanding obligations or payments due\nhereunder prior to such termination or expiration, nor shall it prejudice any other remedies that the Parties may have\nunder this Agreement or Applicable Laws (except as otherwise provided in this Agreement). For greater certainty,\ntermination of this Agreement for any reason shall not affect the obligations and responsibilities of the Parties\npursuant to ARTICLE 1 (Interpretation), ARTICLE 9 (Remedies and Indemnities) (provided that, the obligation to\nmaintain the insurance coverages set forth in Section 9.3 shall only survive for the time period set forth therein),\nARTICLE 10 (Confidentiality), ARTICLE 11 (Dispute Resolution), and Sections 2.9 (Retained Samples) (for the\nperiod set forth therein), 4.4 (Taxes), 5.2 (Product Recalls and Returns)\u037e 5.5 (Customer Questions or Complaints)\n(for a period of [***] from the date of termination or expiration)\u037e 6.2 (Regulatory and Accounting by Antares) (for\nthe period set forth therein), 7.6 (Effects of Expiration or Termination of this Agreement), 12.1 (Agency), 12.2\n(Assignment) 12.5 (Notices), 12.6 (Amendment), 12.7 (Waiver) and 12.10 (Governing Law), all of which survive\nany termination or expiration.\n(g) Termination, relinquishment or expiration of the Agreement for any reason shall be without prejudice to any rights\nwhich shall have accrued to the benefit of either Party prior to (or as a result of, including, without limitation, rights\navailable under law and equity) such termination, relinquishment or expiration. Such termination, relinquishment or\nexpiration shall not relieve either Party from obligations that are expressly indicated to survive termination or\nexpiration of the Agreement.\n7.7 [***].\nARTICLE 8 \nREPRESENTATIONS, WARRANTIES AND COVENANTS\n8.1 Authority. Each Party hereby represents, warrants and covenants to the other Party that: (i) it has the full right and authority\nto enter into this Agreement and to grant to the other Party the rights granted to such other Party under this Agreement, (ii)\nit has obtained all necessary corporate approvals to enter and execute this Agreement, and (iii) that it is not aware of any\nimpediment that would inhibit its ability to perform its obligations hereunder.\n- 26 -\n"}, "__type__": "4"}, "fd689e9f-b884-469a-9d63-14d595f801eb": {"__data__": {"id_": "fd689e9f-b884-469a-9d63-14d595f801eb", "embedding": null, "metadata": {"page_label": "28", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n8.2 AMAG Warranties. AMAG hereby represents, warrants and covenants to Antares as follows:\n(a) AMAG, or a Third Person manufacturing Drug and Pre-Filled Syringes on behalf of AMAG, shall manufacture the\nDrug and Pre-Filled Syringe in accordance with the Specifications, cGLP, cGCP, cGMP and cQSRs, this\nAgreement, the Quality Agreement and Applicable Laws including, without limitation, federal, state, or local laws,\nregulations, or guidelines governing manufacturing at the site where such manufacturing is being conducted\u037e\n(b) AMAG, or a Third Person manufacturing Drug and Pre-Filled Syringes on behalf of AMAG, shall obtain and\nmaintain all necessary licenses, permits and approvals required by Applicable Laws in connection with the\nmanufacture the Drug and Pre-Filled Syringe, and supply of Drug and Prefilled Syringes to Antares or its\nSubcontractor\u037e\n(c) That all Drug or Prefilled Syringes manufactured by AMAG, or a Third Person on behalf of AMAG, when delivered\nto Antares or its Subcontractor (i) will comply with applicable Product Specifications and Certificate of Analysis\n(PFS Manufacture)\u037e (ii) will not be adulterated or misbranded within the meaning of any Applicable Laws effective at\nthe time of delivery and will not be an article which may not be introduced into interstate commerce under any\nApplicable Laws\u037e (iii) will be delivered to Antares or its Subcontractor (as the case may be) free and clear of all liens\nand encumbrances, and (iv) will be in compliance with cGMPs and all Applicable Laws\u037e\n(d) That all Products and sample Products, when released by AMAG for distribution, sale or use pursuant to Section\n2.6(b)(v)(D): (i) will comply with applicable Product Specifications, Batch Record, Certificate of Analysis Certificate\nof Analysis (PFS Manufacture), the Certificate of Analysis (PFS ID Testing), Certificate of Analysis (Product) and\nthe Certificate of Conformance (Product)\u037e (ii) will not be adulterated or misbranded within the meaning of any\nApplicable Laws effective at the time of delivery and will not be an article which may not be introduced into\ninterstate commerce under any Applicable Laws\u037e and (iii) will be in compliance with cGMPs and all Applicable\nLaws\u037e\n(e) Prior to the first commercial sale by AMAG or a Third Person on behalf of AMAG of Products, sample Product\nand Trainers in a given market, the Products, sample Product and Trainers, if labelled and manufactured in\naccordance with the Specifications and in compliance with applicable cGMPs and Applicable Laws, have received\nthe necessary marketing approvals from applicable Regulatory Authorities for sale, distribution and use in such\nmarket\u037e\n- 27 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n8.2 AMAG Warranties. AMAG hereby represents, warrants and covenants to Antares as follows:\n(a) AMAG, or a Third Person manufacturing Drug and Pre-Filled Syringes on behalf of AMAG, shall manufacture the\nDrug and Pre-Filled Syringe in accordance with the Specifications, cGLP, cGCP, cGMP and cQSRs, this\nAgreement, the Quality Agreement and Applicable Laws including, without limitation, federal, state, or local laws,\nregulations, or guidelines governing manufacturing at the site where such manufacturing is being conducted\u037e\n(b) AMAG, or a Third Person manufacturing Drug and Pre-Filled Syringes on behalf of AMAG, shall obtain and\nmaintain all necessary licenses, permits and approvals required by Applicable Laws in connection with the\nmanufacture the Drug and Pre-Filled Syringe, and supply of Drug and Prefilled Syringes to Antares or its\nSubcontractor\u037e\n(c) That all Drug or Prefilled Syringes manufactured by AMAG, or a Third Person on behalf of AMAG, when delivered\nto Antares or its Subcontractor (i) will comply with applicable Product Specifications and Certificate of Analysis\n(PFS Manufacture)\u037e (ii) will not be adulterated or misbranded within the meaning of any Applicable Laws effective at\nthe time of delivery and will not be an article which may not be introduced into interstate commerce under any\nApplicable Laws\u037e (iii) will be delivered to Antares or its Subcontractor (as the case may be) free and clear of all liens\nand encumbrances, and (iv) will be in compliance with cGMPs and all Applicable Laws\u037e\n(d) That all Products and sample Products, when released by AMAG for distribution, sale or use pursuant to Section\n2.6(b)(v)(D): (i) will comply with applicable Product Specifications, Batch Record, Certificate of Analysis Certificate\nof Analysis (PFS Manufacture), the Certificate of Analysis (PFS ID Testing), Certificate of Analysis (Product) and\nthe Certificate of Conformance (Product)\u037e (ii) will not be adulterated or misbranded within the meaning of any\nApplicable Laws effective at the time of delivery and will not be an article which may not be introduced into\ninterstate commerce under any Applicable Laws\u037e and (iii) will be in compliance with cGMPs and all Applicable\nLaws\u037e\n(e) Prior to the first commercial sale by AMAG or a Third Person on behalf of AMAG of Products, sample Product\nand Trainers in a given market, the Products, sample Product and Trainers, if labelled and manufactured in\naccordance with the Specifications and in compliance with applicable cGMPs and Applicable Laws, have received\nthe necessary marketing approvals from applicable Regulatory Authorities for sale, distribution and use in such\nmarket\u037e\n- 27 -\n"}, "__type__": "4"}, "acac135c-09e9-44bd-892a-b02688c2919c": {"__data__": {"id_": "acac135c-09e9-44bd-892a-b02688c2919c", "embedding": null, "metadata": {"page_label": "29", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n(f) AMAG has the requisite legal title and ownership under its intellectual property necessary for it to fulfill its obligations\nunder this Agreement, and that there is no pending or threatened litigation, arbitration, government proceeding, or\ngovernment investigation (and AMAG has not received any communication relating thereto) which alleges that\nAMAG\u2019s past activities relating to the Drug or activities proposed under this Agreement infringe or misappropriate\nany of the intellectual property rights of any Third Person, and to AMAG\u2019s actual knowledge, there is no intellectual\nproperty of any Third Person that would be infringed or misappropriated by Antares or its Subcontractor carrying\nout the Manufacturing Services in accordance with this Agreement\u037e and\n(g) AMAG agrees that federal securities law may prohibit it, its Affiliates and its representatives from purchasing or\nselling any securities of Antares while it is in possession of material, non-public information of Antares, and that it will\nnot disclose any material, non-public information, directly or indirectly, to any party for the purpose of encouraging\nsuch party to trade in Antares\u2019s securities and that it will comply at all times with the applicable securities laws and\nregulations.\n8.3 Antares Warranties. Antares hereby represents, warrants and covenants to AMAG as follows:\n(a) Antares or its Subcontractor shall perform the Manufacturing Services in accordance with the Specifications, cGLP,\ncGCP, cGMPs and cQSRs, this Agreement, the Quality Agreement and Applicable Laws including, without\nlimitation, federal, state, or local laws, regulations, or guidelines governing manufacturing at the Manufacturing Sites\u037e\n(b) Antares or its Subcontractor shall obtain and maintain all necessary licenses, permits and approvals required by\nApplicable Laws in connection with the Manufacturing Services, manufacture of Devices and supply of Products,\nsample Products or Trainers to AMAG\u037e\n(c) As of the Effective Date, Antares has disclosed to AMAG any and all FDA Form 483\u2019s, warning letters or similar\nnotices relating to the Manufacturing Site and import alerts for any other products manufactured in the Manufacturing\nSite issued during the last [***]\u037e\n(d) [***]\u037e\n(e) Antares has the requisite legal title and ownership of intellectual property necessary for it to fulfill its obligations under\nthis Agreement, and that there is no pending or threatened litigation, arbitration, government proceeding, or\ngovernment investigation (and Antares has not received any communication relating thereto) which alleges that\nAntares\u2019 past activities relating to [***] devices or activities proposed under this\n- 28 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n(f) AMAG has the requisite legal title and ownership under its intellectual property necessary for it to fulfill its obligations\nunder this Agreement, and that there is no pending or threatened litigation, arbitration, government proceeding, or\ngovernment investigation (and AMAG has not received any communication relating thereto) which alleges that\nAMAG\u2019s past activities relating to the Drug or activities proposed under this Agreement infringe or misappropriate\nany of the intellectual property rights of any Third Person, and to AMAG\u2019s actual knowledge, there is no intellectual\nproperty of any Third Person that would be infringed or misappropriated by Antares or its Subcontractor carrying\nout the Manufacturing Services in accordance with this Agreement\u037e and\n(g) AMAG agrees that federal securities law may prohibit it, its Affiliates and its representatives from purchasing or\nselling any securities of Antares while it is in possession of material, non-public information of Antares, and that it will\nnot disclose any material, non-public information, directly or indirectly, to any party for the purpose of encouraging\nsuch party to trade in Antares\u2019s securities and that it will comply at all times with the applicable securities laws and\nregulations.\n8.3 Antares Warranties. Antares hereby represents, warrants and covenants to AMAG as follows:\n(a) Antares or its Subcontractor shall perform the Manufacturing Services in accordance with the Specifications, cGLP,\ncGCP, cGMPs and cQSRs, this Agreement, the Quality Agreement and Applicable Laws including, without\nlimitation, federal, state, or local laws, regulations, or guidelines governing manufacturing at the Manufacturing Sites\u037e\n(b) Antares or its Subcontractor shall obtain and maintain all necessary licenses, permits and approvals required by\nApplicable Laws in connection with the Manufacturing Services, manufacture of Devices and supply of Products,\nsample Products or Trainers to AMAG\u037e\n(c) As of the Effective Date, Antares has disclosed to AMAG any and all FDA Form 483\u2019s, warning letters or similar\nnotices relating to the Manufacturing Site and import alerts for any other products manufactured in the Manufacturing\nSite issued during the last [***]\u037e\n(d) [***]\u037e\n(e) Antares has the requisite legal title and ownership of intellectual property necessary for it to fulfill its obligations under\nthis Agreement, and that there is no pending or threatened litigation, arbitration, government proceeding, or\ngovernment investigation (and Antares has not received any communication relating thereto) which alleges that\nAntares\u2019 past activities relating to [***] devices or activities proposed under this\n- 28 -\n"}, "__type__": "4"}, "73be55e9-3465-4092-b40d-36d08ec05fd3": {"__data__": {"id_": "73be55e9-3465-4092-b40d-36d08ec05fd3", "embedding": null, "metadata": {"page_label": "30", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nAgreement infringe or misappropriate any of the intellectual property rights of any Third Person, and to Antares\u2019 actual\nknowledge, there is no intellectual property of any Third Person that would be infringed or misappropriated by AMAG fulfilling\nany of its obligations or exercising any of its rights under this Agreement\u037e and\n(f) Antares agrees that federal securities law may prohibit it, its affiliates and its representatives from purchasing or\nselling any securities of AMAG while it is in possession of material, non-public information of AMAG, and that it will\nnot disclose any material, non-public information, directly or indirectly, to any party for the purpose of encouraging\nsuch party to trade in AMAG\u2019s securities and that it will comply at all times with the applicable Federal Securities\nLaws and regulations.\n(g) [***].\n8.4 Debarred Persons. Each of the Parties covenants, represents and warrants that: (i) neither it nor any of its employees or,\nsubcontractors performing Manufacturing Services have been \u201cdebarred\u201d by the FDA, or subject to a similar sanction\nfrom another Regulatory Authority\u037e nor have debarment proceedings against said Party or any of its employees or\nsubcontractors performing Manufacturing Services been commenced\u037e and (ii) it will not in the performance of its\nobligations under this Agreement use the services of any person debarred or suspended by the FDA as described in 21\nU.S.C. \u00a7335(a) or (b). Said Party will promptly notify the other Party in writing if any such debarment proceedings have\ncommenced or if said Party or any of its employees or subcontractors performing Manufacturing Services are debarred by\nthe FDA or other Regulatory Authorities. Each of the Parties further covenants, represents and warrants that it does not\ncurrently have, and will not hire, as an officer or an employee any person who has been convicted of a felony under the\nlaws of the United States for conduct relating to the regulation of any drug product under the Federal Food, Drug, and\nCosmetic Act.\n8.5 Permits. As between the Parties, AMAG shall be solely responsible for obtaining or maintaining, on a timely basis, any\npermits or other Regulatory Approvals in respect of the Products, sample Products, Trainers, Specifications, including,\nwithout limitation, all marketing and post-marketing approvals.\n8.6 No Warranty. NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, EITHER\nEXPRESSED OR IMPLIED, BY FACT OR LAW, OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS\nAGREEMENT, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF FITNESS FOR A PARTICULAR\nPURPOSE OR WARRANTY OF MERCHANTABILITY OR WARRANTY OF NON-INFRINGEMENT OF\nTHIRD PERSON RIGHTS.\n- 29 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nAgreement infringe or misappropriate any of the intellectual property rights of any Third Person, and to Antares\u2019 actual\nknowledge, there is no intellectual property of any Third Person that would be infringed or misappropriated by AMAG fulfilling\nany of its obligations or exercising any of its rights under this Agreement\u037e and\n(f) Antares agrees that federal securities law may prohibit it, its affiliates and its representatives from purchasing or\nselling any securities of AMAG while it is in possession of material, non-public information of AMAG, and that it will\nnot disclose any material, non-public information, directly or indirectly, to any party for the purpose of encouraging\nsuch party to trade in AMAG\u2019s securities and that it will comply at all times with the applicable Federal Securities\nLaws and regulations.\n(g) [***].\n8.4 Debarred Persons. Each of the Parties covenants, represents and warrants that: (i) neither it nor any of its employees or,\nsubcontractors performing Manufacturing Services have been \u201cdebarred\u201d by the FDA, or subject to a similar sanction\nfrom another Regulatory Authority\u037e nor have debarment proceedings against said Party or any of its employees or\nsubcontractors performing Manufacturing Services been commenced\u037e and (ii) it will not in the performance of its\nobligations under this Agreement use the services of any person debarred or suspended by the FDA as described in 21\nU.S.C. \u00a7335(a) or (b). Said Party will promptly notify the other Party in writing if any such debarment proceedings have\ncommenced or if said Party or any of its employees or subcontractors performing Manufacturing Services are debarred by\nthe FDA or other Regulatory Authorities. Each of the Parties further covenants, represents and warrants that it does not\ncurrently have, and will not hire, as an officer or an employee any person who has been convicted of a felony under the\nlaws of the United States for conduct relating to the regulation of any drug product under the Federal Food, Drug, and\nCosmetic Act.\n8.5 Permits. As between the Parties, AMAG shall be solely responsible for obtaining or maintaining, on a timely basis, any\npermits or other Regulatory Approvals in respect of the Products, sample Products, Trainers, Specifications, including,\nwithout limitation, all marketing and post-marketing approvals.\n8.6 No Warranty. NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, EITHER\nEXPRESSED OR IMPLIED, BY FACT OR LAW, OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS\nAGREEMENT, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF FITNESS FOR A PARTICULAR\nPURPOSE OR WARRANTY OF MERCHANTABILITY OR WARRANTY OF NON-INFRINGEMENT OF\nTHIRD PERSON RIGHTS.\n- 29 -\n"}, "__type__": "4"}, "5ccda36c-5bc1-4428-afc8-f5fd40c0639a": {"__data__": {"id_": "5ccda36c-5bc1-4428-afc8-f5fd40c0639a", "embedding": null, "metadata": {"page_label": "31", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nARTICLE 9 \nREMEDIES AND INDEMNITIES\n9.1 Antares\u2019 Right to Indemnification. AMAG shall indemnify each of Antares, its Affiliates, its Subcontractors and their\nrespective successors and assigns, and the directors, officers, employees, and agents thereof (the \u201c Antares\nIndemnitees\u201d), defend and hold each Antares Indemnitee harmless from and against any and all liabilities, damages,\nlosses, settlements, claims, actions, suits, penalties, fines, costs or expenses (including, without limitation reasonable\nattorneys\u2019 fees) (any of the foregoing, \u201cDamages\u201d) incurred by or asserted against any Antares Indemnitee of whatever\nkind or nature, including, without limitation, any claim or liability based upon negligence, warranty, strict liability, violation of\ngovernment regulation or infringement of patent or other proprietary rights, but only to the extent arising from or occurring\nas a result of a claim or demand made by a Third Person (a \u201c Third Person Claim\u201d) against any Antares Indemnitee\nbecause of (a) breach of any warranty made by AMAG pursuant to Section 8.2 hereof\u037e (b) the Product, sample Product\nor Trainer (including the content of any labelling and the decision to release the Product, sample Product or Trainer) unless\nattributable to an item identified in Section 9.2 below which is under the responsibility of Antares or its Subcontractors\u037e (c)\nthe distribution or detailing of any Product, sample Product or Trainer by or on behalf of AMAG or its sublicensees,\nexcept to the extent such claim is attributable to an item identified in Section 9.2(f) below which is under the responsibility\nof Antares\u037e (d) any allegation that the manufacture, use, sale, offer for sale or importation of a Product, sample Product or\nTrainer infringes any patent, other intellectual property rights or other proprietary rights of a Third Person, except to the\nextent such infringement relates to the manufacture, use, sale, offer for sale or importation of a Device (including a Device\nincorporated into a Product) or any delivery system including the Device\u037e or (e) any breach of this Agreement by AMAG,\nexcept, in each such case, to the extent that such Damages are finally determined to have resulted from the negligence or\nmisconduct of Antares. Antares shall promptly notify AMAG of any Third Person Claim upon becoming aware thereof,\nand shall permit AMAG, at AMAG\u2019s cost, to defend against such Third Person Claim and to control the defense and\ndisposition (including, without limitation, selection its counsel and all decisions to litigate, settle or appeal) of such claim,\nand shall cooperate in the defense thereof. Antares may, at its option and expense, have its own counsel participate in any\nproceeding that is under the direction of AMAG and shall cooperate with AMAG and its insurer in the disposition of any\nsuch matter.\n9.2 AMAG\u2019s Right to Indemnification . Antares shall indemnify each of AMAG, its Affiliates, and their respective\nsuccessors and assigns, and the directors, officers, employees, and agents thereof (the \u201cAMAG Indemnitees\u201d), defend\nand hold each AMAG Indemnitee harmless from and against any and all Damages incurred by or asserted against any\nAMAG Indemnitee of whatever kind or nature, including, without limitation, any claim or liability based upon negligence,\nwarranty, strict liability, violation of government regulation or infringement of\n- 30 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nARTICLE 9 \nREMEDIES AND INDEMNITIES\n9.1 Antares\u2019 Right to Indemnification. AMAG shall indemnify each of Antares, its Affiliates, its Subcontractors and their\nrespective successors and assigns, and the directors, officers, employees, and agents thereof (the \u201c Antares\nIndemnitees\u201d), defend and hold each Antares Indemnitee harmless from and against any and all liabilities, damages,\nlosses, settlements, claims, actions, suits, penalties, fines, costs or expenses (including, without limitation reasonable\nattorneys\u2019 fees) (any of the foregoing, \u201cDamages\u201d) incurred by or asserted against any Antares Indemnitee of whatever\nkind or nature, including, without limitation, any claim or liability based upon negligence, warranty, strict liability, violation of\ngovernment regulation or infringement of patent or other proprietary rights, but only to the extent arising from or occurring\nas a result of a claim or demand made by a Third Person (a \u201c Third Person Claim\u201d) against any Antares Indemnitee\nbecause of (a) breach of any warranty made by AMAG pursuant to Section 8.2 hereof\u037e (b) the Product, sample Product\nor Trainer (including the content of any labelling and the decision to release the Product, sample Product or Trainer) unless\nattributable to an item identified in Section 9.2 below which is under the responsibility of Antares or its Subcontractors\u037e (c)\nthe distribution or detailing of any Product, sample Product or Trainer by or on behalf of AMAG or its sublicensees,\nexcept to the extent such claim is attributable to an item identified in Section 9.2(f) below which is under the responsibility\nof Antares\u037e (d) any allegation that the manufacture, use, sale, offer for sale or importation of a Product, sample Product or\nTrainer infringes any patent, other intellectual property rights or other proprietary rights of a Third Person, except to the\nextent such infringement relates to the manufacture, use, sale, offer for sale or importation of a Device (including a Device\nincorporated into a Product) or any delivery system including the Device\u037e or (e) any breach of this Agreement by AMAG,\nexcept, in each such case, to the extent that such Damages are finally determined to have resulted from the negligence or\nmisconduct of Antares. Antares shall promptly notify AMAG of any Third Person Claim upon becoming aware thereof,\nand shall permit AMAG, at AMAG\u2019s cost, to defend against such Third Person Claim and to control the defense and\ndisposition (including, without limitation, selection its counsel and all decisions to litigate, settle or appeal) of such claim,\nand shall cooperate in the defense thereof. Antares may, at its option and expense, have its own counsel participate in any\nproceeding that is under the direction of AMAG and shall cooperate with AMAG and its insurer in the disposition of any\nsuch matter.\n9.2 AMAG\u2019s Right to Indemnification . Antares shall indemnify each of AMAG, its Affiliates, and their respective\nsuccessors and assigns, and the directors, officers, employees, and agents thereof (the \u201cAMAG Indemnitees\u201d), defend\nand hold each AMAG Indemnitee harmless from and against any and all Damages incurred by or asserted against any\nAMAG Indemnitee of whatever kind or nature, including, without limitation, any claim or liability based upon negligence,\nwarranty, strict liability, violation of government regulation or infringement of\n- 30 -\n"}, "__type__": "4"}, "72bec2df-05da-4b85-b31d-e150ada60e0a": {"__data__": {"id_": "72bec2df-05da-4b85-b31d-e150ada60e0a", "embedding": null, "metadata": {"page_label": "32", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\npatent or other proprietary rights, but only to the extent arising from or occurring as a result of a Third Person Claim against any\nAMAG Indemnitee because of (a) breach of any warranty made by Antares pursuant to Section 8.3 hereof\u037e (b) any alleged defect\nin the design or functionality of the Device\u037e (c) the failure by Antares or its Subcontractors to provide the Manufacturing Services\naccording to Specifications, except to the extent AMAG approved such failure pursuant to its in process acceptance activities set\nforth in the Quality Agreement\u037e (d) [***]\u037e (e) the warehousing or shipping of a Product, sample Product or Trainer by Antares,\nexcept to the extent such claim alleges infringement of any patent, other intellectual property rights or other proprietary rights of a\nThird Person\u037e (f) any allegation that the Manufacturing Services performed under this Agreement or the manufacture, use, sale,\noffer for sale or importation of a Device (including a Device incorporated into a Product) or any delivery system including the\nDevice, in such cases, infringes any patent, other intellectual property rights or other proprietary rights of a Third Person\u037e or (g)\nany breach of this Agreement by Antares, except, in each such case, to the extent that such Damages are finally determined to\nhave resulted from the negligence or misconduct of AMAG or a sublicensee of AMAG. AMAG shall promptly notify Antares of\nany Third Person Claim upon becoming aware thereof, and shall permit Antares at Antares\u2019 cost to defend against such Third\nPerson Claim and to control the defense and disposition (including, without limitation, selection its counsel and all decisions to\nlitigate, settle or appeal) of such Third Person Claim and shall cooperate in the defense thereof. AMAG may, at its option and\nexpense, have its own counsel participate in any proceeding that is under the direction of Antares and will cooperate with Antares\nor its insurer in the disposition of any such matter.\n9.3 Insurance. Each Party shall obtain and maintain commercial general liability insurance, including product liability insurance\ncovering the obligations of that Party under this Agreement through the Term and for a period of [***] thereafter, which\ninsurance shall afford limits of not less than (i) $[***] for each occurrence\u037e and (ii) $[***] in the aggregate per annum.\nSuch insurance may be provided in more than one separate insurance policy and/or on claims made or claims made and\nreported forms as is common in the insurance marketplace for similar risks. If requested each Party will provide the other\nwith a current and valid certificate of insurance evidencing the above and showing the name of the issuing company, the\npolicy number, the effective date, the expiration date and the limits of liability. If a Party is unable to maintain the insurance\npolicies required under this Agreement through no fault on the part of such Party, then such Party shall forthwith notify the\nother Party in writing and the Parties shall in good faith negotiate appropriate amendments to the insurance provision of this\nAgreement in order to provide adequate assurances.\n9.4 Limitation of Liability.\n[***].\n- 31 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\npatent or other proprietary rights, but only to the extent arising from or occurring as a result of a Third Person Claim against any\nAMAG Indemnitee because of (a) breach of any warranty made by Antares pursuant to Section 8.3 hereof\u037e (b) any alleged defect\nin the design or functionality of the Device\u037e (c) the failure by Antares or its Subcontractors to provide the Manufacturing Services\naccording to Specifications, except to the extent AMAG approved such failure pursuant to its in process acceptance activities set\nforth in the Quality Agreement\u037e (d) [***]\u037e (e) the warehousing or shipping of a Product, sample Product or Trainer by Antares,\nexcept to the extent such claim alleges infringement of any patent, other intellectual property rights or other proprietary rights of a\nThird Person\u037e (f) any allegation that the Manufacturing Services performed under this Agreement or the manufacture, use, sale,\noffer for sale or importation of a Device (including a Device incorporated into a Product) or any delivery system including the\nDevice, in such cases, infringes any patent, other intellectual property rights or other proprietary rights of a Third Person\u037e or (g)\nany breach of this Agreement by Antares, except, in each such case, to the extent that such Damages are finally determined to\nhave resulted from the negligence or misconduct of AMAG or a sublicensee of AMAG. AMAG shall promptly notify Antares of\nany Third Person Claim upon becoming aware thereof, and shall permit Antares at Antares\u2019 cost to defend against such Third\nPerson Claim and to control the defense and disposition (including, without limitation, selection its counsel and all decisions to\nlitigate, settle or appeal) of such Third Person Claim and shall cooperate in the defense thereof. AMAG may, at its option and\nexpense, have its own counsel participate in any proceeding that is under the direction of Antares and will cooperate with Antares\nor its insurer in the disposition of any such matter.\n9.3 Insurance. Each Party shall obtain and maintain commercial general liability insurance, including product liability insurance\ncovering the obligations of that Party under this Agreement through the Term and for a period of [***] thereafter, which\ninsurance shall afford limits of not less than (i) $[***] for each occurrence\u037e and (ii) $[***] in the aggregate per annum.\nSuch insurance may be provided in more than one separate insurance policy and/or on claims made or claims made and\nreported forms as is common in the insurance marketplace for similar risks. If requested each Party will provide the other\nwith a current and valid certificate of insurance evidencing the above and showing the name of the issuing company, the\npolicy number, the effective date, the expiration date and the limits of liability. If a Party is unable to maintain the insurance\npolicies required under this Agreement through no fault on the part of such Party, then such Party shall forthwith notify the\nother Party in writing and the Parties shall in good faith negotiate appropriate amendments to the insurance provision of this\nAgreement in order to provide adequate assurances.\n9.4 Limitation of Liability.\n[***].\n- 31 -\n"}, "__type__": "4"}, "01941cb9-258c-4b72-b432-c4ccab276a20": {"__data__": {"id_": "01941cb9-258c-4b72-b432-c4ccab276a20", "embedding": null, "metadata": {"page_label": "33", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nARTICLE 10 \nCONFIDENTIALITY\nArticles 17 and 18 of the Development and License Agreement are hereby incorporated by reference herein and made a part of\nthis Agreement.\nARTICLE 11 \nDISPUTE RESOLUTION\n11.1 Commercial Disputes. In the event of any dispute arising out of or in connection with this Agreement [***], the Parties\nshall first try to solve it amicably. In this regard, any Party may send a notice of dispute to the other, and each Party shall\nappoint, within [***] from receipt of such notice of dispute, a senior executive representative having full power and\nauthority to solve the dispute. The representatives so designated shall meet as necessary in order to solve such dispute. If\nthe dispute has not been resolved within [***] after the end of the [***] negotiation period referred to above (which\nperiod may be extended by mutual agreement), then such dispute shall be subject to any other remedy available under this\nAgreement or at law or equity.\n11.2 [***].\nARTICLE 12 \nMISCELLANEOUS\n12.1 Agency. Neither Party is, nor shall be deemed to be, an employee, agent, co-venturer or legal representative of the other\nParty for any purpose. Neither Party shall be entitled to enter into any contracts in the name of, or on behalf of the other\nParty, nor shall either Party be entitled to pledge the credit of the other Party in any way or hold itself out as having the\nauthority to do so.\n12.2 Assignment. Except as otherwise provided in this Section 12.2, neither this Agreement nor any interest hereunder shall be\nassignable by any Party without the prior written consent of the other (which consent shall not be unreasonably withheld,\nconditioned or delayed)\u037e provided, however, that either Party may assign this Agreement to any wholly-owned subsidiary\nor to any successor by merger or sale of substantially all of its business unit to which this Agreement relates. This\nAgreement shall be binding upon the successors and permitted assignees of the Parties. Any purported assignment in\nviolation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the\npurported assignee.\n12.3 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such\nother acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.\n- 32 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nARTICLE 10 \nCONFIDENTIALITY\nArticles 17 and 18 of the Development and License Agreement are hereby incorporated by reference herein and made a part of\nthis Agreement.\nARTICLE 11 \nDISPUTE RESOLUTION\n11.1 Commercial Disputes. In the event of any dispute arising out of or in connection with this Agreement [***], the Parties\nshall first try to solve it amicably. In this regard, any Party may send a notice of dispute to the other, and each Party shall\nappoint, within [***] from receipt of such notice of dispute, a senior executive representative having full power and\nauthority to solve the dispute. The representatives so designated shall meet as necessary in order to solve such dispute. If\nthe dispute has not been resolved within [***] after the end of the [***] negotiation period referred to above (which\nperiod may be extended by mutual agreement), then such dispute shall be subject to any other remedy available under this\nAgreement or at law or equity.\n11.2 [***].\nARTICLE 12 \nMISCELLANEOUS\n12.1 Agency. Neither Party is, nor shall be deemed to be, an employee, agent, co-venturer or legal representative of the other\nParty for any purpose. Neither Party shall be entitled to enter into any contracts in the name of, or on behalf of the other\nParty, nor shall either Party be entitled to pledge the credit of the other Party in any way or hold itself out as having the\nauthority to do so.\n12.2 Assignment. Except as otherwise provided in this Section 12.2, neither this Agreement nor any interest hereunder shall be\nassignable by any Party without the prior written consent of the other (which consent shall not be unreasonably withheld,\nconditioned or delayed)\u037e provided, however, that either Party may assign this Agreement to any wholly-owned subsidiary\nor to any successor by merger or sale of substantially all of its business unit to which this Agreement relates. This\nAgreement shall be binding upon the successors and permitted assignees of the Parties. Any purported assignment in\nviolation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the\npurported assignee.\n12.3 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such\nother acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.\n- 32 -\n"}, "__type__": "4"}, "dfbee3d2-60f0-48bc-97b0-6e4a0a6ca719": {"__data__": {"id_": "dfbee3d2-60f0-48bc-97b0-6e4a0a6ca719", "embedding": null, "metadata": {"page_label": "34", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n12.4 Force Majeure. Neither Party shall be liable to the other for loss or damages or shall have any right to terminate this\nAgreement for any default or delay attributable to any force majeure event outside of the affected Party\u2019s reasonable\ncontrol, including, but not limited to, acts of God, acts of government, war, fire, flood, earthquake, terrorist acts, strike,\nlabor dispute and the like (each, a \u201cForce Majeure Event\u201d), if the Party affected shall give prompt notice of any such\ncause to the other Party. The Party giving such notice shall thereupon be excused from such of its obligations hereunder as\nit is disabled by the Force Majeure Event from performing for so long as it is so disabled\u037e provided, however, that such\naffected Party commences and continues to take reasonable and diligent actions to cure such cause throughout such\ndisability.\n12.5 Notices. All notices and other communications hereunder shall be in writing and shall be deemed given if delivered\npersonally or by electronic mail or facsimile transmission (receipt verified), telexed, mailed by registered or certified mail\n(return receipt requested), postage prepaid, or sent by express courier service, to the Parties at the following addresses (or\nat such other address for a Party as shall be specified by like notice\u037e provided, that notices of a change of address shall be\neffective only upon receipt thereof):\nIf to AMAG, addressed to: AMAG Pharmaceuticals, Inc.\n[***] 1100 Winter Street\nWaltham, MA 02451\n[***]\nWith a copy to:\n[***]\nAMAG Pharmaceuticals, Inc.\n100 Winter Street\nWaltham, MA 02451\n[***]\nIf to Antares, addressed to: Antares Pharma, Inc.\n[***] 100 Princeton South, Suite 300\nEwing, NJ 08628\n[***]\nwith a copy to:\nGeneral Counsel Antares Pharma, Inc.\n100 Princeton South, Suite 300\nEwing, NJ 08628\n[***]\n- 33 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n12.4 Force Majeure. Neither Party shall be liable to the other for loss or damages or shall have any right to terminate this\nAgreement for any default or delay attributable to any force majeure event outside of the affected Party\u2019s reasonable\ncontrol, including, but not limited to, acts of God, acts of government, war, fire, flood, earthquake, terrorist acts, strike,\nlabor dispute and the like (each, a \u201cForce Majeure Event\u201d), if the Party affected shall give prompt notice of any such\ncause to the other Party. The Party giving such notice shall thereupon be excused from such of its obligations hereunder as\nit is disabled by the Force Majeure Event from performing for so long as it is so disabled\u037e provided, however, that such\naffected Party commences and continues to take reasonable and diligent actions to cure such cause throughout such\ndisability.\n12.5 Notices. All notices and other communications hereunder shall be in writing and shall be deemed given if delivered\npersonally or by electronic mail or facsimile transmission (receipt verified), telexed, mailed by registered or certified mail\n(return receipt requested), postage prepaid, or sent by express courier service, to the Parties at the following addresses (or\nat such other address for a Party as shall be specified by like notice\u037e provided, that notices of a change of address shall be\neffective only upon receipt thereof):\nIf to AMAG, addressed to: AMAG Pharmaceuticals, Inc.\n[***] 1100 Winter Street\nWaltham, MA 02451\n[***]\nWith a copy to:\n[***]\nAMAG Pharmaceuticals, Inc.\n100 Winter Street\nWaltham, MA 02451\n[***]\nIf to Antares, addressed to: Antares Pharma, Inc.\n[***] 100 Princeton South, Suite 300\nEwing, NJ 08628\n[***]\nwith a copy to:\nGeneral Counsel Antares Pharma, Inc.\n100 Princeton South, Suite 300\nEwing, NJ 08628\n[***]\n- 33 -\n"}, "__type__": "4"}, "a73a8431-d562-4196-8f4d-2272ad6e9877": {"__data__": {"id_": "a73a8431-d562-4196-8f4d-2272ad6e9877", "embedding": null, "metadata": {"page_label": "35", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n12.1 Amendment. No amendment, modification or supplement of any provision of the Agreement shall be valid or effective\nunless made in writing and signed by a duly authorized officer of each Party.\n12.2 Waiver. No provision of the Agreement shall be waived by any act, omission or knowledge of a Party or its agents or\nemployees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of\nthe waiving Party. No waiver of any term, provision or condition of this Agreement whether by conduct or otherwise in any\none or more instances shall be deemed to be or construed as a further or continuing waiver of any such term, provision or\ncondition or of any other term, provision or condition of this Agreement.\n12.3 Counterparts\u037e Electronic Copies. The Agreement may be executed simultaneously in two or more counterparts, either\none of which need not contain the signature of more than one Party but both such counterparts taken together shall\nconstitute one and the same agreement. A facsimile transmission or portable document format (PDF) electronic\ntransmission of this signed Agreement by a Party\u2019s authorized representative shall be legal and binding upon such Party.\n12.4 Descriptive Headings. The descriptive headings of this Agreement are for convenience only, and shall be of no force or\neffect in construing or interpreting any of the provisions of this Agreement.\n12.5 Governing Law\u037e Choice of Forum. This Agreement shall be governed by and interpreted in accordance with the\nsubstantive laws of the State of New York, without regard to its conflict of law provisions. The Parties agree that the\nUnited Nations Convention on Contracts for the International Sale of Goods does not apply to this Agreement. Except as\notherwise provided in ARTICLE 11, all claims and proceedings under this Agreement shall be brought exclusively in the\nstate or federal courts of competent subject matter jurisdiction in New York City, State of New York. The Parties hereby\nwaive (i) any objection which it may have at any time to the venue of the proceeding in any such court, (ii) any claim that\nsuch proceedings have been brought in an inconvenient forum, and (iii) the right to object, with respect to such\nproceedings, that such court does not have any jurisdiction over such Party.\n12.6 Severability. Whenever possible, each provision of the Agreement will be interpreted in such manner as to be effective\nand valid under Applicable Law, but if any provision of the Agreement is held to be prohibited by or invalid under\nApplicable Law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the\nremainder of the Agreement. In the event of such invalidity, the Parties shall seek to agree on an alternative enforceable\nprovision that preserves the original purpose of this Agreement.\n- 34 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n12.1 Amendment. No amendment, modification or supplement of any provision of the Agreement shall be valid or effective\nunless made in writing and signed by a duly authorized officer of each Party.\n12.2 Waiver. No provision of the Agreement shall be waived by any act, omission or knowledge of a Party or its agents or\nemployees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of\nthe waiving Party. No waiver of any term, provision or condition of this Agreement whether by conduct or otherwise in any\none or more instances shall be deemed to be or construed as a further or continuing waiver of any such term, provision or\ncondition or of any other term, provision or condition of this Agreement.\n12.3 Counterparts\u037e Electronic Copies. The Agreement may be executed simultaneously in two or more counterparts, either\none of which need not contain the signature of more than one Party but both such counterparts taken together shall\nconstitute one and the same agreement. A facsimile transmission or portable document format (PDF) electronic\ntransmission of this signed Agreement by a Party\u2019s authorized representative shall be legal and binding upon such Party.\n12.4 Descriptive Headings. The descriptive headings of this Agreement are for convenience only, and shall be of no force or\neffect in construing or interpreting any of the provisions of this Agreement.\n12.5 Governing Law\u037e Choice of Forum. This Agreement shall be governed by and interpreted in accordance with the\nsubstantive laws of the State of New York, without regard to its conflict of law provisions. The Parties agree that the\nUnited Nations Convention on Contracts for the International Sale of Goods does not apply to this Agreement. Except as\notherwise provided in ARTICLE 11, all claims and proceedings under this Agreement shall be brought exclusively in the\nstate or federal courts of competent subject matter jurisdiction in New York City, State of New York. The Parties hereby\nwaive (i) any objection which it may have at any time to the venue of the proceeding in any such court, (ii) any claim that\nsuch proceedings have been brought in an inconvenient forum, and (iii) the right to object, with respect to such\nproceedings, that such court does not have any jurisdiction over such Party.\n12.6 Severability. Whenever possible, each provision of the Agreement will be interpreted in such manner as to be effective\nand valid under Applicable Law, but if any provision of the Agreement is held to be prohibited by or invalid under\nApplicable Law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the\nremainder of the Agreement. In the event of such invalidity, the Parties shall seek to agree on an alternative enforceable\nprovision that preserves the original purpose of this Agreement.\n- 34 -\n"}, "__type__": "4"}, "bf0572ac-662f-4036-80cd-1f4f1f024b8e": {"__data__": {"id_": "bf0572ac-662f-4036-80cd-1f4f1f024b8e", "embedding": null, "metadata": {"page_label": "36", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n12.7 Entire Agreement of the Parties. This Agreement, including the Exhibits attached hereto, the Quality Agreement and the\nDevelopment and License Agreement constitute and contain the complete, final and exclusive understanding and agreement\nof the Parties hereto, and cancels and supersedes any and all prior negotiations, correspondence, understandings and\nagreements, whether oral or written, between the Parties respecting the subject matter hereof. In the event there is a\ndiscrepancy between the Exhibits and the Agreement, the Agreement shall control, provided that to the extent there is a\ndiscrepancy between the Quality Agreement and the Agreement, the Quality Agreement shall control with respect to\nquality-related matters\u037e and this Agreement shall control with respect to all other matters. Furthermore, to the extent that\nany provision of this Agreement is inconsistent with any provision of the Development and License Agreement, this\nAgreement shall control and then only to the extent of the inconsistency. For the avoidance of doubt, this Agreement\nsupersedes and replaces Sections 10.2 and 10.3 of the Development and License Agreement.\n12.8 Jointly Prepared. This Agreement has been prepared jointly by both Parties and shall not be strictly construed against\neither Party.\n[Signature page follows.]\n- 35 -\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\n12.7 Entire Agreement of the Parties. This Agreement, including the Exhibits attached hereto, the Quality Agreement and the\nDevelopment and License Agreement constitute and contain the complete, final and exclusive understanding and agreement\nof the Parties hereto, and cancels and supersedes any and all prior negotiations, correspondence, understandings and\nagreements, whether oral or written, between the Parties respecting the subject matter hereof. In the event there is a\ndiscrepancy between the Exhibits and the Agreement, the Agreement shall control, provided that to the extent there is a\ndiscrepancy between the Quality Agreement and the Agreement, the Quality Agreement shall control with respect to\nquality-related matters\u037e and this Agreement shall control with respect to all other matters. Furthermore, to the extent that\nany provision of this Agreement is inconsistent with any provision of the Development and License Agreement, this\nAgreement shall control and then only to the extent of the inconsistency. For the avoidance of doubt, this Agreement\nsupersedes and replaces Sections 10.2 and 10.3 of the Development and License Agreement.\n12.8 Jointly Prepared. This Agreement has been prepared jointly by both Parties and shall not be strictly construed against\neither Party.\n[Signature page follows.]\n- 35 -\n"}, "__type__": "4"}, "85e00777-9dd1-4434-955e-a8489d44b669": {"__data__": {"id_": "85e00777-9dd1-4434-955e-a8489d44b669", "embedding": null, "metadata": {"page_label": "37", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nIN WITNESS WHEREOF, the duly authorized representatives of the Parties have executed this Agreement as of the date\nfirst written above.\nANTARES PHARMA, INC.\nBy: /s/ Patrick Madsen\nName: Patrick Madsen\nTitle: Senior Vice President, Operations\nAMAG PHARMACEUTICALS, INC.\nBy: /s/ William K. Heiden\nName: William K. Heiden\nTitle: President and Chief Executive Officer\n[Signature Page to Manufacturing Agreement]\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nIN WITNESS WHEREOF, the duly authorized representatives of the Parties have executed this Agreement as of the date\nfirst written above.\nANTARES PHARMA, INC.\nBy: /s/ Patrick Madsen\nName: Patrick Madsen\nTitle: Senior Vice President, Operations\nAMAG PHARMACEUTICALS, INC.\nBy: /s/ William K. Heiden\nName: William K. Heiden\nTitle: President and Chief Executive Officer\n[Signature Page to Manufacturing Agreement]\n"}, "__type__": "4"}, "7cf92a9c-9947-4d1b-810c-f91bff25b670": {"__data__": {"id_": "7cf92a9c-9947-4d1b-810c-f91bff25b670", "embedding": null, "metadata": {"page_label": "38", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT A\nLONG LEAD TIME MATERIALS\nPart Name Material Specification Lead-Time\n[***] [***] [***]\n[***] [***] [***]\n[***] [***] [***]\n[***] [***] [***]\n[***] [***] [***]\n[***] [***] [***]\n[***]\n[***] [***]\n[***] [***]\n[***] [***] [***]\n[***] [***] [***]\n[Exhibit A to Manufacturing Agreement]\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT A\nLONG LEAD TIME MATERIALS\nPart Name Material Specification Lead-Time\n[***] [***] [***]\n[***] [***] [***]\n[***] [***] [***]\n[***] [***] [***]\n[***] [***] [***]\n[***] [***] [***]\n[***]\n[***] [***]\n[***] [***]\n[***] [***] [***]\n[***] [***] [***]\n[Exhibit A to Manufacturing Agreement]\n"}, "__type__": "4"}, "a32e30f6-1bed-4d4c-b038-0a8ba4b57385": {"__data__": {"id_": "a32e30f6-1bed-4d4c-b038-0a8ba4b57385", "embedding": null, "metadata": {"page_label": "39", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT B\nPRODUCT SPECIFICATIONS\n[***]\n[Exhibit B to Manufacturing Agreement]\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT B\nPRODUCT SPECIFICATIONS\n[***]\n[Exhibit B to Manufacturing Agreement]\n"}, "__type__": "4"}, "0db47e31-f909-4685-8a93-49388af812c8": {"__data__": {"id_": "0db47e31-f909-4685-8a93-49388af812c8", "embedding": null, "metadata": {"page_label": "40", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT C\nTRAINER SPECIFICATIONS\n[***]\n[Exhibit C to Manufacturing Agreement]\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT C\nTRAINER SPECIFICATIONS\n[***]\n[Exhibit C to Manufacturing Agreement]\n"}, "__type__": "4"}, "d5067db9-db96-4db3-89fc-f730a44a945a": {"__data__": {"id_": "d5067db9-db96-4db3-89fc-f730a44a945a", "embedding": null, "metadata": {"page_label": "41", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT D\nTRANSFER PRICE\nThe \u201cTransfer Price\u201d to be paid by AMAG to Antares for each Product, sample Product and Trainer delivered to AMAG or\nAMAG\u2019s designee under this Agreement during the Term shall be determined as follows:\n[***]\n[Exhibit D to Manufacturing Agreement]\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT D\nTRANSFER PRICE\nThe \u201cTransfer Price\u201d to be paid by AMAG to Antares for each Product, sample Product and Trainer delivered to AMAG or\nAMAG\u2019s designee under this Agreement during the Term shall be determined as follows:\n[***]\n[Exhibit D to Manufacturing Agreement]\n"}, "__type__": "4"}, "ae0fd291-9307-44f4-9597-fb83b6caf4f7": {"__data__": {"id_": "ae0fd291-9307-44f4-9597-fb83b6caf4f7", "embedding": null, "metadata": {"page_label": "42", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT E\nQUALITY AGREEMENT\n[***]\n[Exhibit E to Manufacturing Agreement]\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT E\nQUALITY AGREEMENT\n[***]\n[Exhibit E to Manufacturing Agreement]\n"}, "__type__": "4"}, "57f579ad-c38f-47df-90f2-3c59071d7b70": {"__data__": {"id_": "57f579ad-c38f-47df-90f2-3c59071d7b70", "embedding": null, "metadata": {"page_label": "43", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT F\nBATCH NUMBERING AND EXPIRATION DATES\n[***]\n[Exhibit F to Manufacturing Agreement]\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT F\nBATCH NUMBERING AND EXPIRATION DATES\n[***]\n[Exhibit F to Manufacturing Agreement]\n"}, "__type__": "4"}, "b7e7b712-bc61-4105-8a1c-6f46db70b0cf": {"__data__": {"id_": "b7e7b712-bc61-4105-8a1c-6f46db70b0cf", "embedding": null, "metadata": {"page_label": "44", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT G\nRETAINED SAMPLES\nPart Number Description\n[***] [***]\n[***] [***]\n[***] [***]\n[***] [***]\n[Exhibit G to Manufacturing Agreement]\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT G\nRETAINED SAMPLES\nPart Number Description\n[***] [***]\n[***] [***]\n[***] [***]\n[***] [***]\n[Exhibit G to Manufacturing Agreement]\n"}, "__type__": "4"}, "ba8eca35-e4d3-4d5d-96c4-2b3c05f0ca00": {"__data__": {"id_": "ba8eca35-e4d3-4d5d-96c4-2b3c05f0ca00", "embedding": null, "metadata": {"page_label": "45", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT H\nINITIAL FORECAST\n[***]\n[Exhibit H to Manufacturing Agreement]\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT H\nINITIAL FORECAST\n[***]\n[Exhibit H to Manufacturing Agreement]\n"}, "__type__": "4"}, "3cf96726-0699-4654-b7dd-d9ed96f4d9be": {"__data__": {"id_": "3cf96726-0699-4654-b7dd-d9ed96f4d9be", "embedding": null, "metadata": {"page_label": "46", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT I\nREDUNDANCY PLAN\nItem Financial Responsibility Primary Back-up On Hand\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[Exhibit I to Manufacturing Agreement]\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT I\nREDUNDANCY PLAN\nItem Financial Responsibility Primary Back-up On Hand\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[***] [***] [***] [***]\n[Exhibit I to Manufacturing Agreement]\n"}, "__type__": "4"}, "b09aaba8-326e-452f-bfec-ad3e1366d6e0": {"__data__": {"id_": "b09aaba8-326e-452f-bfec-ad3e1366d6e0", "embedding": null, "metadata": {"page_label": "47", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT J\n[***]\n[Exhibit J to Manufacturing Agreement]\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT J\n[***]\n[Exhibit J to Manufacturing Agreement]\n"}, "__type__": "4"}, "f940fc46-7f9f-4c4b-9a5a-47aeafa725c3": {"__data__": {"id_": "f940fc46-7f9f-4c4b-9a5a-47aeafa725c3", "embedding": null, "metadata": {"page_label": "48", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT K\nAMAG EQUIPMENT\nThe following molds:\nPart Number Description\n[***] [***]\n[***] [***]\n[***] [***]\n[Exhibit K to Manufacturing Agreement]\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT K\nAMAG EQUIPMENT\nThe following molds:\nPart Number Description\n[***] [***]\n[***] [***]\n[***] [***]\n[Exhibit K to Manufacturing Agreement]\n"}, "__type__": "4"}, "68235fb7-ec05-4d76-991d-28ed5e83c444": {"__data__": {"id_": "68235fb7-ec05-4d76-991d-28ed5e83c444", "embedding": null, "metadata": {"page_label": "49", "file_name": "Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_path": "C:\\Users\\Om Nagvekar\\OneDrive\\Documents\\KIT Assaignment & Notes& ISRO\\Intel Unnati\\Business Contract Validation\\Final Project\\data\\Manufacturing\\Antares Pharma, Inc. - Manufacturing Agreement.PDF", "file_type": "application/pdf", "file_size": 289942, "creation_date": "2024-07-08", "last_modified_date": "2024-07-08"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text_resource": {"embeddings": null, "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT L\nFORM OF CHANGE ORDER\n[***]\n[Exhibit L to Manufacturing Agreement]\n", "path": null, "url": null, "mimetype": null}, "image_resource": null, "audio_resource": null, "video_resource": null, "text_template": "{metadata_str}\n\n{content}", "class_name": "Document", "text": "[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL\nSUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2\nPROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED\nEXHIBIT L\nFORM OF CHANGE ORDER\n[***]\n[Exhibit L to Manufacturing Agreement]\n"}, "__type__": "4"}}, "docstore/metadata": {"1df29f49-542f-4632-9766-56b644975a8e": {"doc_hash": "7497014f62bece671993ea4bd016fdc0c64c415bbc54fb670e6ccc48175613ef"}, "c982e2fa-d5ea-4eeb-bc3f-abe002c61bd5": {"doc_hash": "17a58b32d4426861aa9422d90101698c1b6e4af9fa408ce396422108969de390"}, "e376513c-5f5c-48b2-85ec-e29f792187c7": {"doc_hash": "9bd90e9f5889286f76f4d26e9e82b7fcd1264317d0859376dea9210b5d3c2245"}, "65e9c1b8-a1c9-4d1b-9dad-0c204a02ea11": {"doc_hash": "5317124216c39f89e9df6b2662dbf97e9f0acb7819c7f6d7c1a425ff28de9ace"}, "84df9f27-aff5-4154-b7d6-cd797ebd3d52": {"doc_hash": "9375862477e86eaeabf5e2910174ec8f06ff3b7c2988017b7be2b3b68b8e3226"}, "833a5be3-8773-4bb2-82bf-8142494da7f1": {"doc_hash": "691e4566a65b921eab965638194d62b4240e975687119497288577698e5254cb"}, "905ae161-c71b-4477-8324-7086a6f969ce": {"doc_hash": "d9859966977af800e000ba7be1752abf29689442af7a56ad4dba6c55b6cb13e9"}, "d1fdc44d-9a11-4eb9-9f3b-6360aa8d35e3": {"doc_hash": "597c5e78e6ff3570276c23dc58cbe4392171d3262b63f0e93cc48f33ad5f4d69"}, "55d06dca-b0a4-44fe-81c4-6de36ab5f3ef": {"doc_hash": "8d95d44ac908823efd4e5f83d5b20d52672843ebde29ade7adea70f04119559d"}, "bbd2446f-f033-470e-9e16-07cc043bb645": {"doc_hash": "1c7988f3da3260a938e0bac904e1851536ae1e2770c08740b6880f32c63c728f"}, "ecad764f-1548-409b-8119-f302fa9fb8a4": {"doc_hash": "4d0c2f61d7331809f1d535540cd88baf1cd786f71c4ef720375c4305277f53d4"}, "0cf1d310-a344-4bed-81c6-d4fa859c4005": {"doc_hash": "70c0381c127988dac30b201919f20cf6892aff66246139832f478d7906890caa"}, "dff0578e-3119-404e-aa01-a44032763200": {"doc_hash": "cab4f2198e0cc97d5f48b8b2600464d8ec78a1c1c524a9014a945e7b214e602b"}, "c777efec-389f-48b3-b95c-048455221178": {"doc_hash": "310817ef5bdfca85371562167bb25296688b16112058c41cf032b95a68065c19"}, "ab447eb3-fd4d-4fd3-8ce9-b3c691e45cc8": {"doc_hash": "6f7d361bebbfeac44c5163c3766de93cab28a8f06c785355d6a1f3e588cc9ed5"}, "d5cc2269-0675-4fff-afb2-57f439132826": {"doc_hash": "1670ee62c705ae98809c493615ef112d9c8c722e6a44b92cd7529e026c17ae4b"}, "de01b267-2b71-41f4-a82a-dbda4bd63e39": {"doc_hash": "f0fe3c7bf39754fc7ea015aae2a7d49a05c3dc317d696970d13caaf1520d20fa"}, "b2f47ca2-e351-4963-ba66-4775b64b4c9b": {"doc_hash": "40787d499181f4cf0118da424ef835d91b738db156a20ac0c200efbc2e81846a"}, "de8b5ea7-5f16-4a1c-8b3c-2187b50b46ad": {"doc_hash": "f02780eced0d704fd82a660cd9aec072b3d40bfbc6950a963bc4696e658a1817"}, "fabd1597-72ac-4dcf-9acc-d97cc9f6a2e7": {"doc_hash": "a17d001ead09150f550d4f2e69469cc500c2e5be96d5c17d5a5011bf401c20a2"}, "7be6d76d-4153-4b2a-8195-dce079e20453": {"doc_hash": "bf2480222c82a46ec3986435d62e9d3a3f58ffdaac5f790426392d5b16fd03a6"}, "92065c78-1e41-4794-b2b8-1a97e26684fe": {"doc_hash": "fd8d6be5cbe6640b4e94f1d68d22cf35488f98a5d6d2e86a8a9657d7cc0a3e50"}, "a1f5fe48-be6e-466b-9c51-d1192e12fcf5": {"doc_hash": "402a4b2ead8abda56471d825099f45be0b4ac96f8691b46d5f37ed84f0cf25bf"}, "80fcf24d-2508-4ee0-8d82-763f5aa4db2c": {"doc_hash": "c63acb740d69d362c692f7a218826557bf2d08c347536015b61e4975d24c1476"}, "07a25142-cc33-43f8-a952-994c8f584fc2": {"doc_hash": "699cf13a1da7f09f457800d29f2ffaa4d31e837f38d2227194b11f5f2effa922"}, "a94ad7fe-4e06-4ced-9b0b-0919bc313f64": {"doc_hash": "c4ed5d38dcfb92ff6dfe4940123e09d5b79de46565f4e008ef46163ced52c4fe"}, "1a1c442d-8b85-4512-adca-0d80e14d0a40": {"doc_hash": "4f4ed41efe1107ab747cac6aeeff0d36f0276284c9579586d45288b5f4dbdb31"}, "fd689e9f-b884-469a-9d63-14d595f801eb": {"doc_hash": "53fe7c21b1918f9e6fe4c98a4cc077c6d8653c89ec52aef3d7a16b23fa189c41"}, "acac135c-09e9-44bd-892a-b02688c2919c": {"doc_hash": "6d2a506815f2bf87877bde043fed2b1c1edf7ceb18b65325d42ab22ee371c2f6"}, "73be55e9-3465-4092-b40d-36d08ec05fd3": {"doc_hash": "786c0a00ef2fb9211e80db36f3d06d33272c0cb5049143e4fb94ebcc149ad72c"}, "5ccda36c-5bc1-4428-afc8-f5fd40c0639a": {"doc_hash": "327e58e8dc62b7d56fdf0a566a912f3c298b28c0a083922725f1c30a5835c043"}, "72bec2df-05da-4b85-b31d-e150ada60e0a": {"doc_hash": "ddf5babb060f7372ba21a4ce46e7176bcbad97afd510fe13f0d8b1b9dc95defd"}, "01941cb9-258c-4b72-b432-c4ccab276a20": {"doc_hash": "7aebe84cee285c44dc13ce9c73fa5f817b4a18d1640ea36536a8cbb45d0488d3"}, "dfbee3d2-60f0-48bc-97b0-6e4a0a6ca719": {"doc_hash": "249e32f3a138d1f4946f7d4f71efbc1708df55887a9b8cb4ab8b2f3e437fdcd4"}, "a73a8431-d562-4196-8f4d-2272ad6e9877": {"doc_hash": "95d65c9fb1f784b90664efc7d72578cfde49a4cfa9c76d0d22a8ee6dbda0dd48"}, "bf0572ac-662f-4036-80cd-1f4f1f024b8e": {"doc_hash": "fb58e30b64c0475063fc8a19d53e6c12b1ca2a79dec24be7ac57c1a19e765ab9"}, "85e00777-9dd1-4434-955e-a8489d44b669": {"doc_hash": "f6bf7582a86e57ddadf55aec6d25c5816fd1993522663c26a4559a7f916bc9c4"}, "7cf92a9c-9947-4d1b-810c-f91bff25b670": {"doc_hash": "fbf83b7cf4e0f8d745b446edf57f707cf853527aff5b8824ff340fc6a26cffd0"}, "a32e30f6-1bed-4d4c-b038-0a8ba4b57385": {"doc_hash": "e6fea187b9244cfaf5fac93952813eabece879ea3f746aac2adba416991c51dc"}, "0db47e31-f909-4685-8a93-49388af812c8": {"doc_hash": "52fdde492aa2ef494c33f5685557b3e69ae8759572445f439c1373b6402ec6d4"}, "d5067db9-db96-4db3-89fc-f730a44a945a": {"doc_hash": "4df319b6d2fbea293f4cd208a7b6e69047106a30a9113e19fe53c397bfac2d77"}, "ae0fd291-9307-44f4-9597-fb83b6caf4f7": {"doc_hash": "b55b213618a122f501eef15f32f71e0ec2632f0f2f04713c875efd06bd917ef9"}, "57f579ad-c38f-47df-90f2-3c59071d7b70": {"doc_hash": "da63bad5c4cb57ba8419338ccf0f66562e773d4517288b10307a705bd24d784d"}, "b7e7b712-bc61-4105-8a1c-6f46db70b0cf": {"doc_hash": "e10723c4de1ae739d4f6609c713f00b92cace88ba50d66498648d37316682af1"}, "ba8eca35-e4d3-4d5d-96c4-2b3c05f0ca00": {"doc_hash": "530696d53b64931f190f6b7a3b4e905f2c299587170b3cbf312d31288280f667"}, "3cf96726-0699-4654-b7dd-d9ed96f4d9be": {"doc_hash": "e11277150dc5c464e84bcb31524ae91ac2b42f354b808054ad4c376ac4229dd6"}, "b09aaba8-326e-452f-bfec-ad3e1366d6e0": {"doc_hash": "7c7ead1a76e47770c27cfc42a3d063650cbe785878d49bab6e85e6f53d68f55f"}, "f940fc46-7f9f-4c4b-9a5a-47aeafa725c3": {"doc_hash": "e5bd314552b06a873a8eadcd134d1fc4f0f004b9b5d570ee5a077c8087340871"}, "68235fb7-ec05-4d76-991d-28ed5e83c444": {"doc_hash": "2e5ac38ec0ad1b05fe0a07d5cbff435ead51eb95c13d264a7cc1917fc41f0ae1"}}}